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1 Introduction
1.1 The TGF-ß superfamily
The transforming growth factor (TGF-ß) superfamily is a large family of highly conserved
growth-regulatory polypeptides that includes the TGFs, activins, inhibins, bone morphogenetic
proteins (BMPs), Müllerian-inhibiting substance, nodal, glial-derived neurotrophic factor, and
lefty (Massagué 1990, 1997; Meno et al. 1996; Lin et al. 1993; Zhou et al. 1993; Roberts and
Sporn 1990). Members of the TGF-ß superfamily exert a wide range of biological effects on a
large variety of cell types: they regulate cell growth, differentiation, immune surveillance,
matrix production and apoptosis. Many of them have important functions during embryonic
development in pattern formation and tissue specification; in the adult they are involved in
processes such as tissue repair and modulation of the immune system (reviewed by Heldin
1997).
1.1.1 The structural characteristics of the TGF-ß superfamily members
The TGF-ß superfamily members are synthesized as larger precursor molecules with a signal
sequence of 15-25 amino acids, a pro-domain of 50-375 amino acids, and a C-terminal mature
region of 110-140 amino acids that mostly contains 7-9 cysteine residues (Fig. 1.1.A; Hogan et
al. 1994). The C-terminal mature region can be released by being cleaved at the RXXR site.
The mature, biologically active forms of TGF-ß superfamily members are typically homo- or
heterodimers of two cysteine-rich, 12-15 kDa subunits, linked by a single disulfide bond
(reviewed by Hoodless and Wrana 1998) (Fig. 1.1.B).
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Fig. 1.1: Structure of  TGF-ß superfamily members.
(A) TGF-ß-related proteins are synthesized as larger precursor proteins (Hogan et al. 1994; Kingsley 1994).
(B) Schematic structure of the mature region of TGF-ß. Six of the characteristic cysteine residues form three
disulfide bonds within each monomer subunit. The seventh cysteine forms a disulfide bond linking two
monomers into a dimer (Kingsley 1994).
1.1.2 The members and subfamilies within the TGF-ß superfamily
At present there are 43 proteins isolated from various species ranging from Drosophila to
mammals that belong to the TGF-ß superfamily. Based on comparison of the C-terminal
mature regions the members can be classified into distinct subgroups with highly related
sequences such as the TGFß-subfamily, the activin-subfamily, the dpp-subfamily, the
60A-subfamily and the GDF-subfamily (Derynck and Feng 1997; Wozney and Rosen 1998).
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Fig. 1.2: The TGF-ß superfamily. Most TGF-ß-related factors listed are of vertebrate origin except that DPP,
60A, and Screw are Drosophila proteins, univin is from sea urchin and Vg-1 is a Xenopus protein (Derynck
and Feng 1997).
The Dpp and 60A subfamilies are related more closely to each other than to TGF-ßs or
activins and have often been grouped together as part of a larger collection of molecules called
DVR (dpp and Vg1 related) (Lyons et al. 1989) or BMP superfamily (Hogan 1996a).  The
Drosophila decapentaplegic (dpp) gene (Padgett et al. 1987), the BMP2 and BMP4 (Wozney
et al. 1988; Wozney 1989), Drosophila gene 60A (Wharton et al. 1991; Doctor et al. 1992),
BMP5, BMP6 or Vgr-1, BMP7 or osteogenic protein 1 (OP-1), BMP-8a or osteogenic
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protein 2 (OP-2), and BMP-8b (Celeste et al. 1990; Lyons et al. 1989; Ozkaynak et al. 1990;
Ozkaynak et al. 1992;  Zhao et al. 1996) are all assigned to this subfamily.
1.1.3 Bone morphogenetic proteins
The BMPs (bone morphogenetic proteins) have variously been called osteogenins, osteogenic
proteins, DVR factors and BMPs (reviewed by Kingsley 1994). The name BMP was first
given to three proteins purified from a demineralized bovine bone preparation that induced
ectopic cartilage and endochondral bone formation when implanted in experimental animals
(Wozney et al. 1988).
Now it is clear that the name BMP is misleading because there is strong genetic and
experimental evidence that these molecules regulate biological processes as diverse as cell
proliferation, apoptosis, differentiation, cell-fate determination, and morphogenesis. Moreover,
the vertebrate BMPs are involved in the development of nearly all organs and tissues, as well
as in critical steps in the establishment of the basic embryonic body plan (Hogan 1996).
Although many roles have been assigned to the bone morphogenetic proteins, one of the key
functions of BMP-like proteins in vertebrates is to induce formation of cartilage, bone, and the
supporting tissues of the skeleton. 
The use of purified individual bone morphogenetic protein molecules produced in recombinant
systems has clarified the activity of many bone morphogenetic proteins. The implantation of
recombinant human BMP2 with a suitable carrier of murine ectopic intramuscula or
subcutaneous sites results in chondrogenesis and osteogenesis (Wang et al. 1990). Other bone
morphogenetic proteins qualitatively show similar effects. Bone morphogenetic protein 4, as
expected given its high degree of sequence similarity to BMP2, also induces new bone
formation in this system. The less closely related molecules, BMP6 and BMP7 seem to induce
bone at similar levels as BMP2, though a third member of this subgroup BMP5, requires
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higher amounts of protein to induce similar amounts of bone (Gitelman et al. 1994; Sampath et
al. 1992; Wozney and Rosen 1993).
Many of the BMPs have been observed to affect differentiation of cells into cartilage and bone
phenotypes by cell culture experiments examining the activities of bone morphogenetic
proteins on various cell types, including embryonic and adult cells and cell lines derived from
calvarial and long bone sources, in vitro (Ahrens et al. 1993; Rosen et al. 1996).
Identification of the regulatory elements controlling bone morphogenetic protein expression
has shown that BMPs are integral parts of signaling cascades that involve several other gene
families. Depending on the developmental system analysed, BMPs induce the expression of
sonic and indian hedgehog, muscle segment homeobox genes, fibroblast growth factors and
PTH/PTHrP receptors, genes shown to play fundamental roles in bone formation and
chondrogenesis (Bitgood and McMahon 1995; Hattersley et al. 1995; Vortkamp et al. 1996;
Zou and Niswander 1996). Conversely, sonic hedgehog, muscle segment homeobox genes,
and retinoic acid all have been shown to affect BMP transcription and seem to be positive
regulators of BMPs (reviewed by Hogan 1996a, b; Wozney and Rosen 1998).
1.2 The receptors of TGF-ß superfamily members
Members of the TGF-ß superfamily signal through a conserved family of transmembrane
serine/threonine kinase receptors, all of which have a short, cysteine-rich extracellular domain,
which was called ‘cysteine box’ (Childs et al. 1993), a single hydrophobic transmembrane
domain, and an intracellular serine/threonine kinase domain (Attisano and Wrana 1996;
Massagué and Weis-Garcia 1996; Miyazono et al. 1994). Functional characterization and
comparison of their primary amino acid sequences indicates that these receptors can be divided
into two classes, the type I receptors and the type II receptors. Unique to type I receptors in
the cytoplasmic domain is a highly conserved 30 amino acid region proceeding the kinase
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domain (Wrana et al. 1994b). This region contains a characteristic SGSGSG motif and is
therefore known as ‘GS domain’, which is of crucial importance in signal transduction.
Fig. 1.3: Signaling receptors for TGF-ß superfamily members (reviewed by Kingsley 1994).
Considerable biochemical and genetic data have shown that signaling by TGF-ß-like factors
occurs through heteromeric complexes of type I and type II receptors. In the absence of
ligand, both type II and type I receptors appear to exist as independent homo-oligomers on the
cell surface (ten Dijke et al. 1996). The type II receptor has constitutive kinase activity (Wrana
et al. 1994a). Heterotetrameric complex formation is initiated when ligand binds to type II
receptor, which then leads to recruitment of receptor I. This complex is likely to contain at
least two molecules of each receptor (Weis-Garcia et al. 1996; Yamashita et al. 1994). The
type II receptor then phosphorylates receptor I at serine and threonine residues within the ‘GS
domain’ (Souchelnytskyi et al. 1996; Wieser et al. 1995). Phosphorylation of the GS domain
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stimulates intracellular responses to the bound ligand (Wrana et al. 1994a; Attisano et al.1996;
Massagué and Weis-Garcia 1996).
1.3 The Smad family
To identify signaling pathways that mediate the activities of TGF-ß family members, emphasis
has been placed on the identification and characterization of proteins that associate with and
are phosphorylated by the serine/threonine kinase receptors. Many proteins have therefore
been identified including TRIP-1 (TGF-ß-receptor interacting protein-1), FT-α (farnesyl
transferase-α), apolipoprotein J/clusterin and FKBP12 (FK506/rapamycin binding protein)
(Attisano and Wrana 1996) by yeast two-hybrid screens using the receptors as bait. These
proteins may play a regulatory role in receptor function, but there is little evidence to indicate
that they are actually required for signaling by TGF-ß ligands. 
Genetic screens lead to two components which may be directly involved in TGF-ß family
members signal transduction: a MAP kinase kinase kinase (TAK1, TGF-ß-activated kinase-1),
and the family of proteins related to the Drosophila gene Mothers against dpp (MAD)
(reviewed by Hoodless and Wrana 1998).
TAK-1 is a novel MAP kinase kinase kinase (MAPKKK). Its associated activator, TAB1
(TAK-1 binding protein), provides additional support for the induction of a kinase cascade by
TGF-ß (Yamaguchi et al. 1995; Shibuya et al. 1996). TAK-1 has been shown to be activated
by TGF-ß and BMP-4 but not EGF, and to induce transcriptional activation of the
plasminogen activator inhibitor-1 promoter. Further investigation is necessary to clarify the
role of the TAK-1 pathway in the signaling of TGF-ß superfamily.
Mothers against dpp (MAD) and its homologs have been charaterized recently as important
signaling mediators of the responses to TGF-ß-related factors (Raftery et al. 1995). This led to
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a breakthrough in understanding how signals are transduced from serine/threonine kinase
receptors to the nucleus.
1.3.1 The members of Smad protein family 
The first family member, the Drosophila Mad, was identified in a screen for maternal effect
enhancers of mutations in dpp (Raftery et al. 1995). The related homologs of Mad have been
identified in C. elegans, human, mouse, rat, and Xenopus (Savage et al. 1996; Derynck and
Zhang 1996b; Massagué 1996; Wrana and Attisano 1996). In an attempt to simplify the
nomenclature, the designation smad, an incorporation of sma- and Mad- gene names, has been
suggested for vertebrate homologs of sma and Mad (Derynck et al. 1996a). 
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Fig. 1.4: Members and signaling specificity of the Smad family (Based on Padgett et al. 1998, Kretzschmar &
Massagué 1998 and Massagué et al. 1997). I: receptor-regulated Smads; II: co-Smads; III: anti-Smads.
On the basis of structural and functional criteria, the Smad family can be divided into three
subgroups (Fig. 1.4). The first group comprises those Smads that are direct substrates of the
TGF-ß family receptor kinases, which are called receptor-regulated Smads (Padgett et al.
1998); The second group, co-Smads, includes Smads that are not direct receptor substrates
but participate in signaling by associating with receptor-regulated Smads. Smad4, sma-4 and
Drosophila Medea belong to this group (Liu et al. 1997; Das et al. 1998; Hudson et al. 1998).
The third group consists of Smad6, Smad7 and Drosophila Daughters agaist dpp (Dad), they
inhibit Smad activation and therefore are referred to as anti-Smads (Kretzschmar and
Massagué 1998; Inoue et al. 1998).
1.3.2 Smad protein domains and their function
Smad proteins are molecules of relative molecular mass 42K-60K. They are highly conserved
across species, but have no known structural motifs and bear no resemblance to components
of other signaling pathways (Heldin et al. 1997). All members of this family typically consist of
three regions, each of them encompassing roughly one third of the molecular structure.
The highest level of amino acid sequence similarity is found in the N-terminal and C- terminal
regions, which are referred to as the N and C domains (or the MH1 and MH2 domains),
respectively. In the C domain of the receptor-regulated Smads there is a conserved sequence
SSXS, which can be phosphorylated by type I receptor kinase (Macías-Silva et al. 1996;  
Kretzschmar et al. 1997a). The C domain is regarded as an effector domain (Meersseman et
al.1997). 
In the basal state, the presence of the N domain inhibits the transcriptional and biological
activities of Smad C domains (Hata et al. 1997). But the N domain may not have a purely
inhibitory function. The N domain of Drosophila Mad has specific DNA-binding activity
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which is required for DPP-induced activation of an enhancer within the vestigital
wing-patterning gene (Kim et al. 1997). 
The central proline-rich region (referred to as the linker region or P domain) is more divergent
and of variable length. However, Smad linker regions are highly conserved between close
isoforms. Four repeated PXSP motifs in the linker region of Smad1 can be phosphorylated by
the Erk family of mitogen-activated protein kinases which then prevent nuclear accumulation
of Smad1 and the transcriptional activity of Smad1 in response to BMP (Kretzschmar et al.
1997b). 
1.3.3 Functional specificity of Smads 
Studies on Smads have defined the specificity of these proteins as mediators of TGF-ß-family
signals. Different Smads may mediate different ligand signals: Smad1 and its close homologs
Smad5 and Smad8 are mediators of BMP signals (Yingling et al. 1996; Liu et al. 1996;
Lechleider et al. 1996; Kretzschmar et al. 1997b; Hoodless et al. 1996; Graff et al. 1996). The
recently described Smad9/MADH6 is structurally similar to Smad1 and may also be involved
in BMP signaling (Watanabe  et al. 1997). Smad2 and Smad3 are substrates and mediators of
related TGF-ß and activin receptors in vertebrates (Baker and Harland 1996; Eppert et al.
1996; Graff et al. 1996; Macías-Silva et al. 1996). Smad4 mimics the BMP-like effects as well
as the activin/Vg1-like effects (Lagna et al. 1996). When overexpressed in mammalian cells,
Smad6 shows a very specific inhibition of BMP but not activin/TGF-ß signaling (Hata et al.
1998; Imamura et al. 1997). Transfection of Smad7 blocks activin/TGF-ß signaling (Nakao et
al. 1997; Hayashi et al. 1997). 
1.3.4 Activation of Smads
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Maximum transcriptional effect requires the cooperation between receptor-regulated Smads
and Smad4 (Lagna et al. 1996; Zhang et al. 1996). Activation of type I receptors triggers the
assembly of heteromeric complexes of these two types of Smads by phosphorylation of
receptor-regulated Smads in their C-terminal SSXS motifs. The mechanism may involve a
phosphorylation-induced unfolding of the N- and C-terminal domains, allowing interaction
with Smad4 to occur (Souchelnytskyi et al. 1997). Given the trimeric structure of Smad4 (Shi
et al. 1997), such complexes are hexamers, whose composition depends on the pathway that
has been activated. 
1.3.5 Smads function in the nucleus
Smads are present in both the cytoplasm and nucleus (Hoodless et al. 1996; Newfeld et al.
1996; Graff et al. 1996; Liu et al. 1996). Ligand binding increases accumulation of Smads in
the nucleus (Baker and Harland 1996). Smad4 has an important function in mediating this
process (Zhang et al. 1997). The translocation seems to require phosphorylation of the
receptor-regulated Smads and that N domain may play an inhibitory function by maintaining
them in the cytoplasm, possibly by association with cytosolic components (Baker and Harland
1996). By now two possibilities of nuclear functions of Smads have been referenced: (i) Smads
as coactivators. Two transcription factors have been implicated in downstream signaling of the
Smads. One is FAST-1 (forkhead activin signal transducer-1). Smad2 can complex with
FAST-1 and then transcriptionally activate the promoter of the gene Mix-2 when co-injected
with activin mRNA (Chen, Y. et al. 1996). The other is a zink-finger transcription factor
encoded by the Drosophila gene schnurri (shn) (Arora et al. 1995; Grieder et al 1995). Shn
activity appears to be regulated by Dpp. (ii) Smads bind DNA directly. The N domain of
Drosophila Mad can itself bind to elements within the vestigial (Vg) promoter, suggesting a
sequence-specific binding function that might directly account for the biologic activity of the
Mad protein (Kim et al. 1997). Smad3 and Smad4 have also been shown to bind DNA in a
sequence-specific manner (Yingling et al. 1997; Zawel et al. 1998). 
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1.3.6 A model of Smad function in TGF-ß signaling 
Taken together, the current findings invite a model of receptor signaling and Smads function
(Fig. 1.5), much of which still requires experimental evaluation (Derynck and Zhang 1996;
Derynck and Feng 1997; Heldin et al. 1997; Hu et al. 1998; Kretzschmar and Massagué 1998).
Fig. 1.5: Proposed model for the Smad-dependent TGF-ß signal transduction pathway (Based on Heldin et al.
1997; Hu et al. 1998).
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1.4  The in vitro model of osteoblast-differentiation
There are three major cell types contributing to the skeleton: chondrocytes, which form
cartilage; osteoblasts, which deposit bone matrix and once embedded in bone matrix they
would mature into terminally differentiated osteocytes; and osteoclasts, which resorb bone.
Chondrocytes and osteoblasts are of mesenchymal origin, whereas osteoclasts derive from the
hematopoietic system (Erlebacher et al. 1995). 
Many extracellular factors were identified to be able to modulate mesenchymal differentiation,
including PTH (parathyroid hormone), GDF, and collagens. Embryonic primary cells or
pluripotent mesenchymal cells are used in in vitro studies, which aim at identifying
transcription factors or clarifying the early events in the differentiation of osteoblasts and
chondrocytes. With a cell culture of primary osteoblasts, Owen and Stein have shown the
relationship between proliferation and differentiation during the rat osteoblast developmental
sequence and developed a model (Owen et al. 1990). Accordingly the process comprises three
distinct time periods. (i) The proliferative phase, lasts for the first 10-12 days and is
characterised by the expression of genes associated with cell division e.g. H4 histone, and cell
growth, e.g. c-fos and c-myc. A number of genes associated with the development of
connective tissue, i.e. type I collagen, TGF-ß and fibronectin are also expressed in this phase.
(ii) The matrix development and maturation phase, takes place over days 12-21 and is
characterised by an increase in the expression of alkaline phosphatase, osteopontin and matrix
Gla protein (MGP). (iii) The mineralization phase, is characterized by the progressive
expression of two bone-related genes, osteopontin and osteocalcin, whose expression is
followed by matrix mineralization.
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Fig. 1.6: The reationship between proliferation and differentiation during the rat osteoblast developmental
sequence. The three principal periods of the osteoblast developmental sequence are designated within broken
vertical lines. Commitment periods and restriction points indicated were experimentally established (Owen et
al. 1990).
There are two restriction points in the osteoblast developmental sequence at which important
regulatory signals must be received before the process can proceed further. The first restriction
point occurs when the proliferation is down-regulated and matrix maturation is induced and
the second when mineralization starts. The mechanism how the important signals regulate the
restriction points is unclarified, but BMPs might represent potential candidates in the
regulation.
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1.5  Research aims
BMP2 has been shown to induce cartilage and bone in both ectopic and orthotopic sites in
vivo and to have many different effects on multiple cell types in vitro (Hiraki et al. 1991; Chen
et al. 1991; Takuwa et al. 1991; Yamaguchi et al. 1991). The murine fibroblastic C3H10T1/2
cells, which have been established from an early stage mouse embryo (Reznikoff et al. 1973),
have been shown to be able to differentiate into various mesenchymal pathways giving rise to
myoblasts, adipocytes, chondrocytes and osteoblasts (Taylor and Jones 1979; Wang et al.
1994; Ahrens et al. 1993). Their responses towards TGF-ß and BMP-treatment make this cell
line a useful model system to explore the involvement of factors in various mesenchymal
differentiation processes.
Signaling of TGF-ß and BMPs from membrane receptors into the nucleus is mediated by the
recently identified Smad protein family. The BMP signal transducer Smad1 exhibits a
domain-like organization. The C domains of receptor-regulated Smads harbour the effector
domain; N domains can bind to DNA directly in addition to their inhibitory functions; the role
of the proline-rich linker region is unclear. The C3H10T1/2 developmental in vitro model
system could contribute to elucidating the functions of the three domains, especially the
function of the linker region of Smad1 in the mesenchymal differentiation processes,
particularly with regard to the osteo/chondrogenic development. For this purpose the
C3H10T1/2 cells should recombinantly express Smad1 or Smad1 domains. The resulting
effects on osteo/chondrogenic development should be analyzed by histochemical and genetic
analyses of marker genes typical or specific for osteogenesis, chondrogenesis, but also
adipogenesis. 
Smads are transcriptional activators, and their phosphorylation and translocation to the nucleus
are thought to affect transcriptional regulation of BMP-responsive genes. The exact
mechanism by which Smads regulate transcriptional in-/activation of marker genes is a
important question whose answer will further define the role of Smads in BMP signaling. In
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this regard, the reporter gene assays under the control of promoters from genes like Msx-1,
3TP-Lux, PTH/PTHrP receptor and JunB should be characterized. 
1 Introduction
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2 Results
2.1 Stable recombinant expressions of Smad1 or Smad1-domains into 
murine mesenchymal progenitor C3H10T1/2 and BMP2 expressing 
C3H10T1/2 cells
2.1.1 Smad1 and its domains
The Xenopus Smad1 is a polypeptide of 466 amino acids with two conserved domains: the
N-terminal domain and the C-terminal domain, also called MH1 and MH2 (Hoodless et al.
1996), separated by a proline-rich variable domain: the linker region (reviewed by Kretzschmar
and  Massagué 1998).
Fig. 2. 1: Smad1 and its domains.
The Xenopus Smad1 wild type and deletion mutants were established and obtained from D.
Huylebroeck Laboratory of Molecular Biology, Celgen, University of Leuven. To analyze the
functions of Smad1’s three domains, we have looked at the following domain mutants: Smad1
lacking the N terminal amino acids 1-145 (Smad1 (C+P) domain); Smad1 without amino acids
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1-262 (Smad1 C domain); Smad1 deleted in amino acids 263-466 (Smad1 (N+P) domain);
Smad1 lacking amino acid 145-466 (Smad1 N domain); the fragment containing amino acids
146-262 (Smad1 linker region or Smad1 P domain); and Smad1 lacking amino acids 146-262
(Smad1 (C+N) domain) (Fig. 2.1). In addition, the point mutant G419S, which interferes with
BMP2-dependent Smad1 phosphorylation, was also tested in our experiments.
2.1.2 Recombinant expression of full-length Smad1 and Smad1 domains in 
C3H10T1/2 and BMP2 expressing C3H10T1/2 cells 
The Smad1 constructs were permanently transfected into the murine mesenchymal precursor
C3H10T1/2 cells and the BMP2-transfected C3H10T1/2 cells (C3H10T1/2BMP2) according to
protocol 5.5.6.1 and thereby were stably integrated into the genomes of these cell lines. The
empty expression vector pMT7T3 was transfected into these cells to establish control cell
lines.
The cells (in 12-well-plates) were transfected with 1.5 µg of the expression vectors described
above, and 150ng selection plasmid pAG60 (neoR-selection plasmid, Colbe’re-Garapin et al.
1981) using DOSPER (Boehringer) (Chapter 5.5.6.1). The integration of the selection plasmid
into genomes enables the transfected cells to survive in selection medium containing G418
(500 µg/ml). The control transfection was performed with empty expression vectors. Cells
started to die 7 days after G418 was added to the medium. Within two weeks of selection,
usually 4-10 G418-resistant clones were observed. Single clones were picked and
subcultivated. The selection pressure was maintained during the entire cultivation period.
To check the extent and stability of the expression of various Smad1 constructs in the
transfected C3H10T1/2 and C3H10T1/2BMP2 cells, the various Smad1 constructs and the
control plasmid transfected cells were plated in Roux bottles (80 cm2). After reaching
confluence (arbitrarily termed day 0), differentiation medium (DMEM with 50 µg/ml ascorbic
acid and 10 mM ß-glycerolphosphate) was used for further cultivation. At the indicated time
intervals (2 days before confluence and 0, 4, 7, 10, 13 days postconfluence) the cells were
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harvested and total RNA was isolated by Tri-ReagentRLS (Chapter 5.5.7). SuperScriptTM
Reverse transcriptase was used to synthesize cDNA (Chapter 5.4.1). RT-PCRs (Chapter
5.4.2) were performed with different primers, which are specific for Xenopus Smad1 domains,
to verify the expression of recombinant Smad1 constructs in C3H10T1/2 cells and
C3H10T1/2BMP2 cells. 
Fig. 2.2: RT-PCR analyses of recombinant Smad1 and its domains in C3H10T1/2 and C3H10T1/2BMP2 cells.
Cultivation was 13 days, X = RNA pellet was lost during isolation. 
Fig. 2.2 shows the recombinant stable expression of Xenopus Smad1 and Smad1 domains in
murine C3H10T1/2 cells and in C3H10T1/2BMP2 cells. In the control cells Smad1 is present in a
endogenous way (Fig. 2.34) but was not detected with the primers for Xenopus Smad1. The
level of expression was compariable.
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The inactive human Smad1 point mutant G419S was also transfected into C3H10T1/2 and
C3H10T1/2BMP2 cells to test whether the conserved 419 glycine of Smad1 has a function in the
signal transduction. Fig. 2.3 shows the recombinant stable expression of Smad1G419S in murine
C3H10T1/2 and in C3H10T1/2BMP2 cells. With the human-specific Smad1 primer no signal was
detected in the control cells, although Smad1 is endogenously expressed in the control cells.
Fig. 2.3: RT-PCR analyses of recombinant Smad1G419S in C3H10T1/2 and C3H10T1/2BMP2 cells. Cultivation
was 13 days.
2.2 The morphological changes of cells expressing recombinant full-length Smad1 
and Smad1 domains 
C3H10T1/2 and C3H10T1/2BMP2 cells recombinantly expressing control vector, Smad1 wild
type, Smad1 (C+P) domain, Smad1 C domain, Smad1 (N+P) domain, Smad1 N domain,
Smad1 (N+C) domain, and Smad1 P domain were grown in 10% FCS DME-medium
containing the appropriate selection antibiotics (G418 and/or puromycin). The cells were
plated at a density of 7500 cells /cm2. After reaching confluence 50 µg/ml ascobic acid and 10
mM ß-glycerophosphate were added as specified in the protocol of Owen (1990) for the
cultivation of native osteoblast-like cells. Ascorbic acid supports the synthesis of collagen
(Jeffery and Martin 1966), and ß-glycerolphosphate serves as an additional source of organic
phosphate enabling mineralization (Owen et al. 1990). The morphological differences among
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the control cells and cells expressing recombinant Smad1 and Smad1 domains were
documented by light microscopy.  
Fig. 2.4: The cell morphology of control cell lines: C3H10T1/2 and C3H10T1/2BMP2  cells
A C3H10T1/2 cells, 2 day before confluence
B C3H10T1/2 cells,  at confluence
C C3H10T1/2 cells, 13 days post-confluence
D C3H10T1/2BMP2 cells, 2 day before confluence
E C3H10T1/2BMP2 cells, at confluence
F C3H10T1/2BMP2 cells, 13 days post-confluence
____
  100 µm.
The C3H10T1/2 control cells grew in monolayer, they showed a typical fibroblastic
morphology during proliferation (Fig. 2.4 A); Upon reaching confluence the cells changed
their morphologies in differentiation medium. The cells were closely packed together (Fig. 2.4
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B). 5 or 6 days post-confluence the cell morphology changed from fibroblastic to
cuboidal-shaped cells (Fig. 2.4 C). The C3H10T1/2BMP2 cells lost their original fibroblastic
nature upon reaching confluence, grew in multilayers (Fig 2.4 E). In addition, many adipocytes
(fat cells) were observed in the C3H10T1/2BMP2 cells starting from 7-9 days post-confluence.
The adipocytes were identified by their characteristic phenotypes: there are many lipid droplets
in the cytoplasm (Fig. 2.4 F).
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Fig. 2.5: The cell morphology of C3H10T1/2 cells recombinantly expressing Smad1 and Smad1 domains (10
days postconfluence). ____ 100 µm.
A:  Parental C3H10T1/2 
B:  C3H10T1/2 - Smad1 wt 
C:  C3H10T1/2 - Smad1(C+P) 
D:  C3H10T1/2 - Smad1 C
E:  C3H10T1/2 - Smad1(N+P) 
F:  C3H10T1/2 - Smad1 N 
G:  C3H10T1/2 - Smad1(C+N) 
H:  C3H10T1/2 - Smad1 P
C3H10T1/2 cells expressing recombinant wild type Smad1 (C3H10T1/2-Smad1 wt) grow in
monolayer and have a fibroblastic appearence. Adipocytes were not detected in this cell line.
However, adipocyte formation was observed in C3H10T1/2 cells expressing Smad1 domains
(Fig. 2.5 C-H)
During proliferation, all C3H10T1/2BMP2 cells expressing recombinant Smad1 domains have a
comparable appearence. Upon reaching confluence, these cell lines grew in multilayers and lost
their original fibroblastic phenotypes. Morpholigical differences among various cell lines were
first observed at 7 days post-confluence: The C3H10T1/2BMP2 cells  expressing Smad1 wild
type (C3H10T1/2BMP2-Smad1 wt), C domain (C3H10T1/2BMP2-Smad1 C), (N+P) domain
(C3H10T1/2BMP2-Smad1 (N+P), N domain (C3H10T1/2BMP2-Smad1 N), (C+N) domain
(C3H10T1/2BMP2-Smad1 (C+N)) and P domain (C3H10T1/2BMP2-Smad1P) showed reduced
amounts of adipocytes (Fig. 2.6 B, D, E, F, G, H); in contrast, expression of the Smad1 (C+P)
domain in C3H10T1/2BMP2 cells (C3H10T1/2BMP2-Smad1 (C+P)) resulted in a thick layer of
adipocytes (Fig. 2.6 C, A).
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Fig. 2.6: The cell morphology of C3H10T1/2BMP2 cells expressing Smad1 or its domains (10 days
postconfluence). ____  100 µm.
A:  control C3H10T1/2BMP2 
B:  C3H10T1/2BMP2 - Smad1 wt 
C:  C3H10T1/2BMP2 - Smad1(C+P) 
D:  C3H10T1/2BMP2 - Smad1 C 
E:  C3H10T1/2BMP2 - Smad1(N+P) 
F:  C3H10T1/2BMP2 - Smad1 N 
G:  C3H10T1/2BMP2 - Smad1(C+N) 
H:  C3H10T1/2BMP2 - Smad1 P 
2.2.1  Smad1-domain-dependent formation of osteoblast-like cells identified by 
alkaline phosphatase staining
The two control cell lines (C3H10T1/2 and C3H10T1/2BMP2) and the cells expressing
recombinant full-length Smad1 and Smad1 domains were plated at a density of 7500 cells/cm2
in 6-well-plates. Cells were grown in DMEM supplemented with 10% FCS and G418 or/and
puromycin. After reaching confluence, differentiation medium was used for further cultivation.
At the indicated time intervals the cells were fixed (Chapter 5.5.5) and alkaline phosphatase
staining were performed with Sigma Fast BCIP/NBT tablets (Chapter 5.5.9.1). 
Alkaline phosphatase positive cells exhibiting a stellate ‘osteoblastic’ phenotype could first be
identified at 4 days post-confluence in C3H10T1/2BMP2 cells. The number of positive cells
increased until the end of the cultivation (Fig. 2.7 B, D). In contrast, the parental C3H10T1/2
cells showed only a few faintly stained cells (Fig. 2.7 A, C).
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Fig. 2.7: Osteoblast-like cells identified by alkaline phosphatase staining of the C3H10T1/2 and
C3H10T1/2BMP2 cells (13 days post-confluence). ______   100 µm.
A:   C3H10T1/2 
B:   C3H10T1/2BMP2 
C:   C3H10T1/2 cells, 275-fold magnification
D:   C3H10T1/2BMP2 cells, 275-fold magnification
Fig. 2.8 showed that consistent with the idea that Smad1 is a signaling mediator for BMP2, the
number of alkaline phosphatase positive cells was higher in C3H10T1/2BMP2-Smad1 wt cells
than in C3H10T1/2BMP2 control cells. This stimulationary effect was abolished in
C3H10T1/2BMP2-Smad1G419S cells (Fig. 2.8), confirming that wild type Smad1 has the ability to
stimulate BMP2-dependent osteogenic differentiation in C3H10T1/2 cells, while the G419S
mutation in Smad1 suppresses differentiation, but does not exert a dominant-negative effect.
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Fig. 2.8: Osteoblast-like cells identified by alkaline phosphatase staining of C3H10T1/2BMP2 cells,
C3H10T1/2BMP2-Smad1G419S cells, and C3H10T1/2BMP2-Smad1 wt cells.
A: day 0 
B: 4 day post-confluence
C: 13 day post-confluence
The recombinant expression of the Smad1 (N+P) domain, N domain, (C+N) domain and P
domain did not lead to the development of cells exhibiting alkaline phosphatase activity in
parental C3H10T1/2 cells (Fig. 2.9 A, a; E, e; F, f; G, g; H, h). Only a few stained cells were
observed in C3H10T1/2-Smad1 wt cells (Fig. 2.9 B, b) whereas the C3H10T1/2-Smad1 (C+P)
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cells and C3H10T1/2-Smad1 C cells showed high numbers of alkaline phosphatase-positive
cells (Fig. 2.9 C, c; D, d).
Fig. 2.9: Osteoblast-like cells identified by alkaline phosphatase staining of C3H10T1/2 cells  expressing
recombinant Smad1 or Smad1 domains (10 day post-confluence). 
_____
 100 µm.
A, a: C3H10T1/2 cells; 
B, b: C3H10T1/2-Smad1 wt ; 
C, c: C3H10T1/2-Smad1 (C+P) ;
D, d: C3H10T1/2-Smad1 C; 
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E, e:  C3H10T1/2-Smad1 (N+P);
F, f:   C3H10T1/2-Smad1 N; 
G, g: C3H10T1/2-Smad1 (C+N);
H, h: C3H10T1/2-Smad1 P; 
Fig. 2.10: Osteoblast-like cells identified by alkaline phosphatase staining of C3H10T1/2BMP2 cells expressing
recombinant Smad1 or Smad1 domains (10 day post-confluence). _____  100 µm.
A, a: C3H10T1/2BMP2 ;
B, b: C3H10T1/2BMP2-Smad1 wt;
C, c: C3H10T1/2BMP2-Smad1 (C+P);
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D, d: C3H10T1/2BMP2-Smad1 C;
E, e:  C3H10T1/2BMP2-Smad1 (N+P);
F, f:   C3H10T1/2BMP2-Smad1 N;
G, g: C3H10T1/2BMP2-Smad1 (C+N);
H, h: C3H10T1/2BMP2-Smad1 P;
The recombinant expression of Smad1, Smad1 (C+P) or Smad1 C domains in C3H10T1/2BMP2
cells leads to enhanced levels of alkaline phosphatase positive osteoblast-like cells (Fig. 2.10.
C, c; D, d). Expression of the Smad1 N  domain or (N+P) domain suppressed the
BMP2-dependent alkaline phosphatase activity (Fig. 2.10. F,f; E,e). Also, the typical alkaline
phosphatase staining cells were not observed in C3H10T1/2BMP2- Smad1 (C+N) cells and
C3H10T1/2BMP2- Smad1 P cells (Fig. 2.10. G, g, H, h). 
Summarizing, the Smad1 (C+P) domain and the Smad1 C domain have the potential to
constitutively induce or stimulate the differentiation of C3H10T1/2 or C3H10T1/2BMP2 cells
into osteoblast-like cells. The result supports the conclusion obtained in both the Xenopus
animal cap assay and a Hela (Mv1Lu) one-hybrid assay, that the C domain is the biological
active domain (Meersseman et al. 1997). In addtion, the Smad1 P domain domain has for the
first time been observed as a negative regulator for the BMP2-dependent formation of
osteoblast-like cells.
2.2.2 Chondrocytes identified by Alcin Blue staining in cells expressing 
recombinant full-length Smad1 or Smad1 domains 
Whether the recombinant Smad1 domains have the ability to initiate or stimulate the
differentiation of C3H10T1/2 cells or C3H10T1/2BMP2 cells into chondrocytes was investigated
by Alcian Blue staining. Alcian Blue specifically stains the typical acid proteoglycans of
cartilage. At the indicated time intervals fixed cells were stained with Alcian Blue at pH 2.5
overnight, washed with PBS, and then documented by light microscopy.
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Fig. 2.11: Chondrocytes identified by Alcian Blue staining of C3H10T1/2BMP2 cells expressing recombinant
Smad1 wild type, Smad1 C domain, and Smad1 P domain (13 day post-confluence). 
A: C3H10T1/2BMP2 cells.
B: C3H10T1/2BMP2-Smad1 wt
C: C3H10T1/2BMP2-Smad1 C
D: C3H10T1/2BMP2-Smad1 P
_____
   100 µm.
Alcian Blue positive cells were not observed in parental C3H10T1/2 cells. Also the
C3H10T1/2 cells expressing recombinant Smad1 domains did not give rise to histologically
verified chondrocytes (data not shown). However, Alcian Blue positive cells were identified in
C3H10T1/2BMP2 cells, C3H10T1/2BMP2-Smad1 wt cells, C3H10T1/2BMP2 -Smad1 C cells, and
C3H10T1/2BMP2-Smad1 P cells (Fig. 2.11. A, B, C, D). Interestingly, it seems that the
chondrogenic differentiation potential is neither increased by the recombinant expression of
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either full-length Smad1 or its biologically active domain (C domain) nor inhibited by the
recombinant expression of the Smad1 P domain, which abolished the positive alkaline
phosphatase staining in C3H10T1/2BMP2 cells.
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2.3 The expression of marker genes for osteogenesis, chondrogenesis and 
adipogenesis in cells recombinantly expressing Smad1 or Smad1 domains 
The osteogenic differentiation potential resulting from recombinant expression of Smad1 and
Smad1 domains was investigated histologically in C3H10T1/2 cells and C3H10T1/2BMP2 cells
(Chapter 2.2.1 and 2.2.2). These results were substantiated by genetic analyses of marker
genes typical of or specific for osteogenesis, including the parathyroid hormone receptor,
collagen I, osteopontin, osteonectin, osteocalcin and the osteogenic transcription factor
CBFA1, in the cells expressing Smad1 domains. In addition, the expression of the
chondrogenic marker gene collagen II and of fibroblast growth factor (FGF) receptor 3, as
well as expression of the adipogenic marker gene adipoQ was investigated in our experiments.
Cells (C3H10T1/2 cells and C3H10T1/2BMP2 cells recombinantly expressing Smad1 and Smad1
domains) were plated at a density of 7500 cells/cm2 in Roux flasks. After reaching confluence
the cells were cultivated in differentiation medium (DMEM containing 10% FCS, G418 with
or without Puromycin, 50 µg/ml ascorbic acid and 10 mM ß-glycerophosphate), which was
changed every other day. The cells were harvested at definite time intervals (2 days before and
0, 4, 7, 10, 13 days after reaching confluence) and total RNA was isolated by
TRI-REAGENTLS (Chapter 5.5.7). 5 µg of total RNA was used for cDNA-synthesis (Chapter
5.4.1).
RT-PCR experiments for all cell lines were performed with primer for the housekeeping gene
HPRT (hypoxanthin-guanin-phosphoribosyl-transferase) in order to equalize the amount of
cDNA of different probes (Fig. 2.12). The amount of cDNA used for the subsequent PCRs for
marker genes was adjusted with the computer program-PHORETIX.
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Fig. 2.12: Expression of HPRT in C3H10T1/2 and C3H10T1/2BMP2 cells recombinantly expressing Smad1 or
Smad1 domains (after equalization of cDNAs). 0.5 µl 1:10 cDNA stock solution, 30 cycles at 55°C. x = RNA
pellet was lost during isolation.
2.3.1 Expression of the osteocalcin gene in cells recombinantly expressing Smad1 
or Smad1 domains
Osteocalcin is a small (49 amino acids) Ca2+-binding protein. It is distinguished by its content
of three gamma-carboxyglutamic (Gla) residues. The name osteocalcin derives from the
abundance of this protein in bone tissue (10-20% of the noncollagen protein), and its affinity
for Ca2+ (Hauschka and Gallop 1977). Osteocalcin appears to be a highly specific osteoblast
marker during bone formation (reviewed by Hauschka 1986). The osteocalcin transcription is
regulated by different factors, for example, Vitamin A- and D- receptors, and the jun-fos
complex (AP-1) (Schüle et al. 1990) . 
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RT-PCR with specific primers (Apendix 1: RT-Osteocalcin) was used to monitor the
expression of the osteocalcin gene in C3H10T1/2 and C3H10T1/2BMP2 cells recombinantly
expressing Smad1 and Smad1 domains.
Fig. 2.13: RT-PCR analyses of the expression of osteocalcin gene in C3H10T1/2 and C3H10T1/2BMP2 cells
recombinantly expressing Smad1 and Smad1 domains (after equalization of cDNAs). 1 µl 1:10 cDNA stock
solution, 29 cycles at 57°C. x = RNA was lost during isolation.
In C3H10T1/2 control cells the osteocalcin mRNA is present at only low levels. Whereas in
the control C3H10T1/2BMP2 cells the osteocalcin mRNA level is up-regulated after confluence,
the maximum expression of osteocalcin in the control C3H10T1/2BMP2 cells was observed at
day 10 post-confluence. The Smad1 (C+P) domain, C domain and (N+P) domain stimulated
the osteocalcin expression in C3H10T1/2 and C3H10T1/2BMP2 cells. The C3H10T1/2-Smad1
N cells also showed a transient stimulation of osteocalcin gene expression. Repression of
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osteocalcin expression was found in C3H10T1/2 and C3H10T1/2BMP2 cells expressing Smad1
(C+N) domain and  P domain (Fig. 2.13).
So, osteocalcin mRNA transcription in parental C3H10T1/2 cells is initiated by Smad1 C and
N contained domains, while the Smad1 P domain repressed osteocalcin expression in
C3H10T1/2BMP2 cells.
2.3.2 Expression of PTH/PTHrP-receptor gene in cells recombinantly expressing 
Smad1 or Smad1 domains
The endocrine Parathyroid hormone (PTH) is synthesized by the parathyroid gland and has
been known for decades as a crucial regulator of blood calcium. By causing bone resorption,
renal tubular calcium reabsorption, and activation of vitamin D, PTH raises blood calcium
levels (Chattopadhyay et al. 1996). Many of the actions of PTH and its paracrine analog
PTHrP (PTH-related protein) are mediated by a PTH/PTHrP receptor, a G-coupled receptor
containing seven transmembrane domains (Jüppner et al. 1991). PTH/PTHrP receptor binds
and responds equally to N-terminal fragments both of PTH and PTHrP (Kronenberg et al.
1997). The PTH/PTHrP receptor mRNA is expressed in the PTH target organs, kidney and
bone (Urena et al. 1993). Moreover, the PTH/PTHrP receptor is found on osteoblasts  but not
on osteoclasts (reviewed by Kronenberg 1997).
The expression of PTH/PTHrP receptor in cells recombinantly expressing Smad1 or its
domains was investigated by RT-PCR using appropriate primers (Appendix1: RT-PTH/PTHrP
R).
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Fig. 2.14: RT-PCR analyses of the expression of PTH/PTHrP receptor gene in C3H10T1/2 and C3H10T1/2BMP2
cells recombinantly expressing Smad1 or Smad1 domains (after equalization of cDNAs). 1 µl 1:10 cDNA stock
solution, 30 cycles at 58°C. x = RNA was lost during isolation.
The PTH/PTHrP receptor gene in control C3H10T1/2 cells was hardly detected by RT-PCR,
while in C3H10T1/2BMP2 cells this receptor was expressed during the entire cultivation. The
Smad1 wild type, the C domain, and (C+P) domain are able to stimulate the expression of
PTH/PTHrP receptor in both C3H10T1/2 and C3H10T1/2BMP2 cells. Interestingly, the N
domain and (N+P) domain are also able to increase the level of PTH/PTHrP receptor
transcription in parental C3H10T1/2 cells. However, in C3H10T1/2BMP2 cells the recombinant
expression of N domain seemed inhibitory and reduced the level of BMP2-dependent receptor
transcription. The expression of PTH/PTHrP receptor gene was completely inhibited in
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C3H10T1/2 cells and C3H10T1/2BMP2 cells expressing Smad1 (C+N) domain or Smad1 P
domain (Fig. 2.14).
2.3.3 Expression of collagen I gene in cells expressing recombinant Smad1 or 
Smad1 domains 
In addition to the PTH/PTHrP receptor gene, the collagen I gene is another early regulated
gene in the osteogenic development. Collagen I is the major extracellular matrix protein of
bone, constituting about 90% of the total organic matrix in mature bone. Collagen I is a
primary product of osteoblasts during bone formation, and it is a characteristic marker for the
osteoblast phenotype (Heersche et al. 1992; Helder et al. 1993).
By RT-PCR and a set of specific primers (Apendix 1: RT-Collagen I) the expression of the
collagen I gene in C3H10T1/2 and C3H10T1/2BMP2 cells expressing recombinant Smad1 or
Smad1 domains was investigated. 
The RT-PCR analyses showed that collagen I specific mRNA is expressed in the fibroblastic
parental C3H10T1/2 cells. The wild type Smad1 enhanced the expression of the collagen I in
C3H10T1/2 and C3H10T1/2BMP2 cells. The collagen I mRNA levels were considerably
enhanced in C3H10T1/2-Smad1 C, C3H10T1/2-Smad1 (C+P), C3H10T1/2BMP2-Smad1 C, and
C3H10T1/2BMP2-Smad1 (C+P) cells (Fig. 2.15 A). The Smad1 (N+P) domain and Smad1 N
domain caused a repression of the expression of the collagen I gene in C3H10T1/2 cells. An
inhibition of the expression of collagen I was also observed in C3H10T1/2 and C3H10T1/2BMP2
cells expressing Smad1 (C+N) domain and P domain (Fig. 2.15 B).
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Fig. 2.15: RT-PCR analyses of the expression of collagen I gene in C3H10T1/2 and C3H10T1/2BMP2 cells
recombinantly expressing Smad1 or its domains (after equalization of cDNAs). 0.8 µl 1:10 cDNA stock
solution, 29 cycles at 50°C.  x = RNA was lost during isolation.
2.3.4 The recombinant expression of CBFA1 gene in C3H10T1/2 cells is not 
significantly regulated by Smad1 or Smad1 domains
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CBFA1, also called Pebpα2A (polyoma enhancer-binding protein), is a member of the
core-binding factor (CBF) transcription factors. CBFA1 has a DNA binding domain, runt,
which is homologous to the Drosophila pair-rule gene runt (Kania et al. 1990). CBFA1 was
recently shown to interact with the promoter region of the osteocalcin gene and play an
essential role in osteoblast differentiation (Ducy et al. 1997).
CBF transcription factors are a family of heterodimeric proteins having two unrelated subunits:
a DNA binding α subunit and a non-DNA binding ß subunit. The mammalian CBF α subunits
are encoded by three distinct genes (CBFA1, CBFA2, and CBFA3) (Ito 1996), and a common
ß subunit is encoded by the CBFB gene (reviewed by Speck and Terryl 1995). 
With a set of specific primers which were located in the specific NH2-terminal of the CBFA1
(Appendix1: RT-CBFA1), the expression of CBFA1 gene was investigated in C3H10T1/2 and
C3H10T1/2BMP2 cells expressing recombinant Smad1 or Smad1 domains. 
Fig. 2.16: RT-PCR analyses of the expression of CBFA1 gene in C3H10T1/2 and C3H10T1/2BMP2 cells
recombinantly expressing Smad1 or Smad1 domains (after equalization of cDNAs). 1 µl 1:10 cDNA stock
solution, 35 cycles at 55°C. x = RNA was lost during isolation.
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RT-PCR analyses showed the CBFA1 to be expressed in both C3H10T1/2 cells and
C3H10T1/2BMP2 cells, but BMP2 background did not enhance its expression compared to
parental C3H10T1/2 cells. The Smad1 C domain, N domain and P domain did not affect the
cbfa1 expression either in C3H10T1/2 cells or in C3H10T1/2BMP2 cells (Fig. 2.16). These
results are consistent with the observations by Noda and colleagues, who have demonstrated
that the BMP4/7 heterodimer enhances cbfa1 expression, whereas BMP2 does not enhance its
expression in MC3T3E1 and C2C12 cells (Tsuji et al. 1998). If BMP2 itself does not regulate
the expression of CBFA1, it is conclusive that its signaling mediator Smad1 has no influence
on CBFA1 expression.
2.3.5 Expression of osteopontin gene in cells recombinantly expressing Smad1 or 
Smad1 domains 
Osteopontin is a glycosylated phosphoprotein with a high number of acidic amino acid residues
and constitutes an abundant protein produced by osteoblasts (Mark et al. 1987). It is expressed
along with osteocalcin in relatively late developmental stages (Owen et al. 1990). Osteopontin
has also been observed in various cells, including epidermal cells, kidney, placenta, neuronal
tissue, some cell types of the lymphopoietic system, and chondrocytes, although, at far lower
expression levels (Ahrens et al. 1993). Osteopontin expression is another strong indication for
the osteogenic developmental sequence because it is second only to osteocalcin in the extent
and depth of bone matrix immuno staining (Carlson et al. 1993).
RT-PCR with a set of specific primers (Apendix 1: RT-Osteopontin ) enabled  monitoring of
the expression of the osteopontin gene in C3H10T1/2 and C3H10T1/2BMP2 cells expressing
recombinant Smad1 or Smad1 domains (Fig. 2.17).
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Fig. 2.17: RT-PCR analyses of the expression of osteopontin gene in C3H10T1/2 and C3H10T1/2BMP2 cells
recombinantly expressing Smad1 or Smad1 domains (after equalization of cDNAs). 1 µl 1:10 cDNA stock
solution, 30 cycles at 53°C. x = RNA was lost during isolation.
The expression of osteopontin gene in control C3H10T1/2 cells was down-regulated after
reaching confluence, while in control C3H10T1/2BMP2 cells osteopontin expression was
up-regulated after confluence (Fig. 2.17). Interestingly, Smad1 P domain increased the
osteopontin mRNA levels in C3H10T1/2 cells but not in C3H10T1/2BMP2 cells. The Smad1
wild type, (C+P) domain, C domain, (N+P) domain, and (C+N) domain did not change the
intensity of osteopontin expression in C3H10T1/2 cells. The N domain down-regulated mRNA
levels in both C3H10T1/2 cells and C3H10T1/2BMP2 cells. 
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2.3.6 Expression of osteonectin gene in cells recombinantly expressing Smad1 or
Smad1 domains 
Osteonectin is an acidic phosphoprotein that  was originally found in bone matrix in high
relative abundance and is virtually absent from other tissues (Termine et al. 1981). However,
expression and secretion of osteonectin have also been documented in various other cell types
including chondrocyte of chondroid bone, though, at a far lower level (reviewed by Tracy et
al. 1988). 
By RT-PCR and specific primers (Apendix 1: RT-Osteonectin) the expression of osteonectin
gene in C3H10T1/2 and C3H10T1/2BMP2 cells expressing recombinant Smad1 or Smad1
domains was investigated.
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Fig. 2.18: RT-PCR analyses of expression of the osteonectin gene in C3H10T1/2 and C3H10T1/2BMP2 cells
recombinantly expressing Smad1 or Smad1 domains (after equalization of cDNAs). 0.8 µl 1:10 cDNA stock
solution, 30 cycles at 59.7°C. x = RNA was lost during isolation.
Fig. 2.18 shows that the osteonectin gene was highly expressed in all cell lines monitored. The
Smad1 domains seemed to have no clear effect on the expression of the osteonectin gene.
Thus it seems that osteopontin and osteonectin are only marginally (osteopontin) or not at all
(osteonectin) influenced by Smad1 or Smad1 domains.
2.3.7 Expression of the collagen II gene in cells recombinantly expressing Smad1 or 
Smad1 domains 
Collagen type II is a homotrimer of α (II), and is the principal protein of cartilage (Erlebacher
et al. 1995). The expression of collagen II gene in C3H10T1/2 and C3H10T1/2BMP2 cells
recombinantly expressing Smad1 or Smad1 domains was investigated with the help of specific
primers (Appendix 1: RT-Collagen II) by RT-PCR.
In the early cultivation stage the expression of collagen II can only marginally be detected in
control C3H10T1/2 cells by RT-PCR and is downregulated after day 4 post-confluence (Fig.
2.19). The wild type Smad1 did not significantly alter the expression of the collagen II gene in
C3H10T1/2 cells. Also, the Smad1 (C+P) domain, C domain, (N+P) domain, N domain,
(C+N) domain and P domain did not significantly change the expression of collagen II gene in
C3H10T1/2 cells .
The expression of collagen II in C3H10T1/2BMP2 cells was detected during the entire
cultivation. Again the Smad1 wild type had no influence on collagen II expression levels. The
Smad1 C domain seemed to stimulate the expression of the collagen II gene in the late
cultivation stage in C3H10T1/2BMP2 cells, however, this is questionable, since (C+P) domain
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did not show this increase. None of Smad1 N domain, (N+P) domain, (C+N) domain and P
domain changed collagen II mRNA levels in C3H10T1/2BMP2 cells (Fig. 2.19).
Fig. 2.19: RT-PCR analyses of expression of the collagen II gene in C3H10T1/2 and C3H10T1/2BMP2 cells
recombinantly expressing Smad1 or Smad1 domains (after equalization of cDNAs). 1 µl 1:10 cDNA stock
solution, 30 cycles at 54°C. x = RNA was lost during isolation.
The RT-PCR analyses showed that recombinant Smad1 and Smad1 domains have not affected
the expression of collagen II gene in C3H10T1/2 and C3H10T1/2BMP2 cells. This result
suggested the BMP2-dependent stimulation of collagen II gene expression was not regulated
by Smad1. 
2.3.8  Expression of FGF receptor 3 gene in cells recombinantly expressing Smad1 
or Smad1 domains 
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Fibroblast growth factor receptor 3 (FGFR-3) is one of four distinct membrane-spanning
tyrosine kinases that serve as high affinity receptors for at least nine fibroblast growth factors
(FGFRs) (reviewed by Basilico and Moscatelli 1992). FGFR-3 mRNA is expressed at high
level in the cartilage rudiments of a wide variety of bones (Peters et al. 1992), suggesting a
role for FGFR-3 in bone development. Deng and his colleagues showed that FGFR-3 is
expressed in the proliferation zone of chondrocytes of postnatal mice, and a normal function of
FGFR-3 is to limit rather than promote osteogenesis (Deng et al. 1996).
With a set of specific primers (Appendix1: FGFR-3) the expression of the FGFR-3 gene in
C3H10T1/2 and C3H10T1/2BMP2 cells expressing recombinant Smad1 or Smad1 domains was
investigated by RT-PCR.
.
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Fig. 2.20: RT-PCR analyses of the expression of the FGFR-3 gene in C3H10T1/2 and C3H10T1/2BMP2 cells
recombinantly expressing Smad1 or Smad1 domains (after equalization of cDNAs). 2 µl 1:10 cDNA stock
solution, 30 cycles at 55°C. x = RNA was lost during isolation.
The expression of FGFR-3 was hardly detectable in parental C3H10T1/2 cells,
C3H10T1/2-Smad1 wt cells and C3H10T1/2 cells expressing Smad1 domains. The control
C3H10T1/2BMP2 cells expressed higher levels of FGFR-3 in comparison with C3H10T1/2 cells.
Smad1 wild type, (C+P) domain, C domain, (N+P) domain, N domain, (C+N) domain and P
domain did not change the expression of FGFR-3 in C3H10T1/2BMP2 cells. (Fig. 2.20)
These RT-PCR analyses imply that BMP2 enhances the FGFR-3 gene expression of
C3H10T1/2 cells, but this BMP2-dependent stimulation of the expression of FGFR-3 gene is
not regulated by Smad1 or its domains. 
2.3.9 Expression of an adipogenic marker gene, AdipoQ, in cells recombinantly 
expressing Smad1 or Smad1 domains 
AdipoQ is a polypeptide of 247 amino acids with a secretary signal sequence at the amino
terminus, a collagenous region (Gly-X-Y repeates) and a globular domain. The expression of
adipoQ is highly specific for adipose tissue and is observed exclusively in mature fat cells (Hu
et al. 1996).
The expression of adipoQ in C3H10T1/2 and C3H10T1/2BMP2 cells expressing recombinant
Smad1 or Smad1 domains was investigated with a set of specific primers (Appendix1:
RT-adipoQ) by RT-PCR.
The expression of adipoQ in control C3H10T1/2 cells is hardly detectable (Fig. 2.21), while in
C3H10T1/2 cells recombinantly expressing Smad1 and Smad1 domains adipoQ gene was
expressed at increased levels. In control C3H10T1/2BMP2 cells adipoQ was highly expressed at
the late stages of cultivation (days 7-13 post-confluence). Smad1 wt, (C+P) domain, N domain
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and (C+N) domain did not change the expression of adipoQ in C3H10T1/2BMP2 cells. The
adipoQ gene was weakly expressed in Smad1 C domain, (N+P) domain and P domain
transfected C3H10T1/2BMP2 cells, however, this is suspicious, because the (C+P) domain and N
domain did not affect adipoQ expression (Fig. 2.21).
Fig. 2.21: RT-PCR analyses of the expression of AdipoQ gene in C3H10T1/2 and C3H10T1/2BMP2 cells
recombinantly expressing Smad1 or Smad1 domains (after equalization of cDNAs). 1µl 1:10 cDNA stock
solution, 31 cycles at 55 °C. x = RNA was lost during isolation.
The expression of adipoQ in C3H10T1/2 and C3H10T1/2BMP2 cells expressing recombinant
Smad1 or Smad1 domains leads to the conclusion that adipogenesis might be regulated by this
signaling molecule, but additional factors seem to exert a great influence on the level of  
ongoing adipogenesis.
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2.4 The Smad1 P domain inhibits the Smad1 C domain-dependent 
osteogenesis in C3H10T1/2 cells
The results presented above showed that the Smad1 P domain has inhibitory function on
BMP2-dependent osteogenesis rather than chondrogenesis in C3H10T1/2 cells. This
investigation was extended by demonstrating that inhibitory effects of the Smad1 P domain
exist on Smad1 C domain-induced osteogenesis. The Smad1 P domain was transfected in a
dose-dependent manner (1.25µg/transfection and 2.5 µg/transfection) into C3H10T1/2-Smad1
C cells. The transfections were carried out in 12-well-plates, pBS pAC (de la Luna 1988) was
used as selection plasmid. Single clones were picked. Positive clones were cultivated for 13
days. Fig. 2.22 showed the recombinant Smad1 P domain to be expressed in Smad1 P/1.25
and Smad1 P/2.5 transfected C3H10T1/2-Smad1 C cells by demonstrating synthesis of the
respective mRNA. In control cells no signal was detected with the primers which are specific
for Xenopus Smad1 P domain.
Fig. 2.22:  Recombinant expression of Smad1 P domain in C3H10T1/2-Smad1 C cells by RT-PCR.
Smad1 P /1.25 = 1.25 µg Smad1 P domain / transfection in a well of 12-well-plate
Smad1 P /2.5 = 2.5 µg Smad1 P domain / transfection in a well of 12-well-plate
2.4.1 The Smad1 P domain inhibits Smad1 C domain-dependent formation of  
osteoblast-like cells in C3H10T1/2 
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The alkaline phosphatase activity was investigated in Smad1 P domain transfected
C3H10T1/2-Smad1 C cells by staining with Sigma Fast BCIP/NBT tablets (Chapter 5.5.9.1).
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Fig. 2.23: Alkaline phosphatase staining of C3H10T1/2-Smad1 C cells recombinantly expressing Smad1 P
domain.  ____   100 µm.
A: Day 13 post-confluence; 275-fold magnification
B: Day 13 post-confluence; 85-fold magnification
C: Day 7 post-confluence; 275-fold magnification
D: Day 7 post-confluence; 85-fold magnification
Expression of the Smad1 P/1.25 suppressed the alkaline phosphatase activity in
C3H10T1/2-Smad1 C cells at both day 7 and day 13 post-confluence. This inhibitory influence
on the alkaline phosphatase activity is even more dramatic in C3H10T1/2-Smad1 C cells
expressing Smad1 P/2.5 (Fig. 2.23) suggesting that the Smad1 P domain inhibits Smad1
C-induced formation of osteoblast-like cells in a dose-dependent manner.
2.4.2 The Smad1 P domain inhibits the Smad1 C domain-induced PTH/PTHrP 
receptor gene and osteocalcin gene expression in C3H10T1/2 cells
The Smad1 P domain down-regulates the BMP2-dependent expression of both the osteocalcin
and PTH/PTHrP receptor gene (Chapter 2.3.1 and 2.3.2). The dose-dependent effect of
Smad1 P domain on the PTH/PTHrP receptor and osteocalcin gene expression in
C3H10T1/2-Smad1 C cells confirms this result (Fig. 2.24, 2.25).
Fig. 2.24: RT-PCR analyses of the dose-dependent influence of Smad1 P domain on the expression of the
PTH/PTHrP receptor gene in C3H10T1/2-Smad1 C cells. 1 µl 1:10 cDNA stock solution, 30 cycles at 58°C.
Smad1 P/1.25 = 1.25 µg Smad1 P domain/transfection in a well of 12-well-plate
2 Results
51
Smad1 P/2.5 = 2.5 µg Smad1 P domain/transfection in a well of 12-well-plate
As shown in Fig. 2.24, expression of the PTH/PTHrP receptor gene in C3H10T1/2-Smad1
cells was inhibited by transfection with Smad1 P domain. 
Fig. 2.25: RT-PCR analyses of the dose-dependent influence of Smad1 P domain on the expression of the
osteocalcin gene in C3H10T1/2-Smad1 C cells.
Smad1 P/1.25 = 1.25 µg Smad1 P domain/transfection in a well of 12-well-plate
Smad1 P/2.5 = 2.5 µg Smad1 P domain/transfection in a well of 12-well-plate
The RT-PCR analyses of expression of the PTH/PTHrP receptor gene and osteocalcin gene,
combined with the alkaline phosphatase staining data, have demonstrated that the Smad1 P
domain exerts a repressive effect on the Smad1 C domain-induced osteogenesis in C3H10T1/2
cells. Together with the result that BMP2 induced osteogenesis was to some extent repressed
by Smad1 P domain, one can conclude that Smad1 P domain is a negative regulator of
osteogenetic development in C3H10T1/2 cells. 
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2.5 The linker region of Smad3 does not affect BMP2-dependent 
osteogenesis in C3H10T1/2 cells
The Smad1-P domain has been demonstrated above to suppress the BMP2-dependent
osteogenesis in C3H10T1/2 cells. Two questions remain to be answered regarding the possible
mechanism of this repression. The first question is whether the repression of P domain on the
osteogenesis is a common effect of Smads P domains or whether it is restricted to Smad1 P
domain; the second is which factor might interact with Smad1 P domain to bring about the
repression of the formation of osteoblast-like cells. For these reasons, the linker region of a
TGF-ß/activin signal mediator, Smad3, was cloned and transfected into C3H10T1/2BMP2 cells
to investigate if the BMP2-dependent osteogenesis was affected by Smad3 P domain. It should
be also investigated whether Smad4 is involved in the Smad1 P domain-dependent inhibition of
osteogenesis.
2.5.1 Cloning of the linker domain of Smad3 in the eukaryotic expression vector 
pMT7T3
A human Smad3 cDNA clone was used to isolate the linker region by PCR and cloning
primers with convenient restriction enzyme sites (EcoR1 and Hind III) and an eukaryotic
ribosomal binding site with ATG start codon. The PCR product was inserted into the
EcoR1/Hind III site of the eukaryotic expression vector pMT7T3 (Fig. 2.26). The integration
of the insert and the functional reading frame were verified by DNA-sequence.
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Fig. 2.26: The eukaryotic expression vector pMT7T3
2.5.1.1 PCR-amplification of the linker region of Smad3
The cloning PCR was carried out by ExpandTM High Fidelity PCR System, which is composed
of a unique enzyme mix containing thermostable Taq DNA and Pwo DNA polymerases
(Bernes et al. 1994). 
↓EcoR I
5’ TCGAATTCGCCACCATGATCCCGGCCGAGTTCCCCCCACT             
3’ ATCGAAGCTTTTAACCGTAGGTGACTGGCTGTAG
    ↑Hind III
After amplification, the PCR product was digested with EcoR1/Hind III and  inserted into the
compatible restriction sites in pMT7T3.
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2.5.1.2 Cloning of the PCR-product into pMT7T3
The PCR product was extracted with phenol (Chapter 5.2.6) followed by a restriction
digestion with EcoR I and Hind III for 2 hrs. After separation of the fragments by running a
LMP-agarose gel, the desired band was isolated from the gel (Chapter 5.2.4). The 243 bp
linker region of Smad3 was then ligated with the pMT7T3 expression vector, which had been
cut accordingly with EcoR I and Hind III (Chapter 5.2.1). The ligation was performed with T4
DNA ligase and incubated at 16 °C overnight (Chapter 5.3.10). 1 µl of the ligation mixture
was transformed into the competent cell E. coli SURE (Chapter 5.3.5). After transformation,
clones were tested by PCR (Chapter 5.3.6) to search for positive clones with correct inserts
(Fig. 2.27).
Fig 2.27: Identifying the positive clones by PCR analyses for the presence of linker domain of Smad3 in the
picked clons. ‘-’ = negative control; ‘+’ = positive control; number1-24 = the PCR products from different
clones. 
The nucleotide sequence of the insert (the linker region of SMAD3) of clone 18 was confirmed
by being sequenced with ABI Prism 310 Genetic Analyzer (Chapter 5.4.4.2). Clone 18 was
transfected into C3H10T1/2BMP2 cells. After selection by G418, positive single clones were
picked and cultivated for 13 days. Fig. 2.28 shows the Smad3 P domain was recombinantly
expressed in C3H10T1/2BMP2 cells.
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Fig. 2.28: RT-PCR analyses of recombinant expression of Smad3 P domain in C3H10T1/2BMP2 cells.
2.5.2 The linker region of Smad3 does not affect the BMP2-dependent 
osteoblast-like cells formation in C3H10T1/2 cells
The alkaline phosphatase activity of C3H10T1/2BMP2 cells expressing the linker region of
Smad3 was investigated  as described previously by staining with Sigma Fast BCIP/NBT
tablets (Chapter 5.5.9.1).
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Fig. 2.29: Alkaline phosphatase staining of the C3H10T1/2BMP2 cells expressing the linker region of Smad3.
______
  100 µm.
A, a: C3H10T1/2BMP2 ; day 0 
B, b: C3H10T1/2BMP2 - P domain of Smad3; day 0 
C, c: C3H10T1/2BMP2; day 13 post-confluence
D, d: C3H10T1/2BMP2 -  P domain of Smad3; day 13 post-confluence
As shown in Fig. 2.29, the alkaline phosphatase activity of the C3H10T1/2BMP2 cells was not
influenced by expression of the linker region of Smad3. This result indicates that in contrast to
the P domain of Smad1, the linker region of Smad3 was unable to inhibit the BMP2-dependent
osteoblast-like cells formation in C3H10T1/2 cells.
2.5.3 The linker region of Smad3 does not affect expression of the PTH/PTHrP 
receptor and osteocalcin gene
Expression of the PTH/PTHrP receptor and the osteocalcin gene was described above as being
inhibited by the Smad1 P domain in C3H10T1/2 cells expressing either recombinant BMP2 or
the Smad1 C domain. Whether or not the linker region of Smad3 is able to inhibit or to reduce
the expression of these two osteogenic marker genes in C3H10T1/2BMP2 cells was investigated
by RT-PCR.
Fig. 2.30: RT-PCR analyses of expression of the PTH/PTHrP receptor gene in the C3H10T1/2BMP2 cells
expressing the linker region of Smad3 (after equalization of cDNAs). 1 µl 1:10 cDNA stock solution, 30 cycles
at 59°C.
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As shown in Fig. 2.30, in C3H10T1/2BMP2 cells expressing P domain (linker region) of Smad3,
the PTH/PTHrP receptor mRNA level observed by RT-PCR analyses was not reduced in
comparison with control C3H10T1/2BMP2 cells (Fig. 2.30). 
 
Fig. 2.31: RT-PCR analyses of expression of the osteocalcin in the C3H10T1/2BMP2 cells expressing linker
region of Smad3 (after equalization of cDNAs). 0.2 µl 1:10 cDNA stock solution, 30 cycles at 57°C.
The osteocalcin gene expression in C3H10T1/2BMP2 cells also was not affected by the P domain
of Smad3 (Fig. 2.31). This observation, combined with the PTH/PTHrP receptor gene
expression data (Fig. 2.30) and alkaline phosphatase staining data (Fig. 2.29), leads to the
conclusion that the linker region of Smad3 was unable to influence the BMP2-dependent
osteogenesis in C3H10T1/2 cells. Therefore, the inhibition of osteogenic development by the
Smad1 P domain appears to be a specific property.
2.6 The Smad1 P domain mimics the BMP2-dependent 
down-regulation of  PEX gene expression in C3H10T1/2 cells 
PEX (phosphate regulating neutral endopeptidase on the X chromosome) is a novel neutral
endopeptidase. Like other members of the neutral endopeptidase family, PEX is a type II
integral membrane glycoprotein. Mutations in PEX underlie the phenotypic features of XLH
(X-linked hypophosphatemia), which is the most common cause of heritable vitamin
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D-resistant rickets in human (Rasmussen and Tenenhouse, 1989). PEX may modulate PTH
bioactivity, particularly at the level of the osteoblast, as well as the hormonal and
paracrine/autocrine effects of factors produced by osteoblasts involved in regulating phosphate
reabsorption and mineralization (Lipman et al. 1998).
Expression of the PEX gene in bone is 2-10-fold higher than in other normal tissues examined.
Furthermore, PEX can effectively degrade PTH (Lipman et al. 1998). In one investigation of
our lab PEX has been identified to be expressed in estrogene treated primary rat stroma cells
and to be down-regulated by TGF-ß or BMP2 in mesenchymal progenitor C3H10T1/2 cells
(Lauber 1998). Therefore, whether Smad1-signaling is involved in the BMP2-dependent
down-regulation of PEX gene expression was investigated by RT-PCR with specific primers
(Appendix1: RT-PEX).
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Fig. 2.32: RT-PCR analyses of expression of the PEX gene in C3H10T1/2 and C3H10T1/2BMP2 cells
recombinantly expressing Smad1 or Smad1 domains (after equalization of cDNAs). 1 µl cDNA stock solution,
30 cycles at 52.6°C. x = RNA was lost during isolation.
As mentioned above,  the PEX gene was expressed at a higher level in C3H10T1/2 cells in
comparison with in C3H10T1/2BMP2 cells. Recombinant expression of Smad1 or its domains
such as Smad1 wt, (C+P) domain, C domain, (N+P) domain, and N domain did not
significantly influence PEX expression. However, BMP-mediated repression of PEX gene
expression was mimicked in C3H10T1/2 cells by the Smad1 P domain (Fig. 2.32). Smad1 P
domain is the only fragment which is able to significantly repress the PEX expression in
C3H10T1/2 cells. The repressive effect of Smad1 P domain on PEX expression was confirmed
by RT-PCR analyses of the C3H10T1/2-Smad1 C cells dose-dependently expressing Smad1 P
domain (Fig. 2.33).
Fig. 2.33: RT-PCR analyses of the dose-dependent influence of Smad1 P domain on expression of the PEX
gene in C3H10T1/2-Smad1 C cells (after equalization of cDNAs). 1 µl cDNA stock solution, 31 cycles at
52.6°C.
Therefore, it is likely that the Smad1 P domain exerts biological activities in regard to TGFß or
BMP-mediated signaling. 
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2.7 Endogenous expression of Smad-family members  in C3H10T1/2 and 
C3H10T1/2BMP2 cells
As described in the introduction, Smad1 is a BMP signal mediator, Smad2 and Smad3 are
TGF-ß/Activin/Vg1 signal mediators, and Smad4 is a co-Smad which is needed in both signal
transduction pathways (reviewed by Massagué et al. 1997a). Smad6 and Smad7 are
anti-Smads, that serve to inhibit specific BMP and TGF-ß induced Smad signaling pathways
(reviewed by Kretzschmar and Massagué 1998). To determine whether or not recombinant
expression of Smad1 or its domains influence the endogenous transcriptional levels of Smad1,
Smad2, Smad4 and Smad7, the C3H10T1/2 and C3H10T1/2BMP2 cells recombinantly
expressing Smad1 and its domains were investigated through a set of primers specific for the
murine genes (Appendix1: RT-Smad1, RT-Smad2, RT-Smad3, RT-Smad4 and RT-Smad7) by
RT-PCR.
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Fig. 2.34: RT-PCR analyses of the endogenous expression of Smad1 gene in C3H10T1/2 and C3H10T1/2BMP2
cells recombinantly expressing Smad1 or its domains (after equalization of cDNAs). 2 µl 1:10 cDNA stock
solution, 30 cycles at 59°C. x = RNA was lost during isolation.
Fig. 2.35:  RT-PCR analyses of the endogenous expression of Smad2 gene in C3H10T1/2 and C3H10T1/2BMP2
cells recombinantly expressing Smad1 or its domains (after equalization of cDNAs). 1 µl 1:10 cDNA stock
solution, 30 cycles at 55°C. x = RNA was lost during isolation.
The C3H10T1/2 and C3H10T1/2BMP2 cells recombinantly expressing Smad1 or Smad1
domains showed similar expression levels for endogenous Smad1 as the control cell lines (Fig.
2.34). Expression of Smad2 endogene in all the above cell lines behaved accordingly (Fig.
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2.35). These results suggested that the endogenous expression of Smad1 and Smad2 was not
affected by recombinant Smad1or its domains. 
Fig. 2.36: RT-PCR analyses of the endogenous expression of Smad4 in C3H10T1/2 and C3H10T1/2BMP2 cells
recombinantly expressing Smad1 or Smad1 domains (after equalization of cDNAs). 1 µl 1:10 cDNA stock
solution, 30 cycles at 60°C. x = RNA was lost during isolation.
As shown in Fig. 2.36, the recombinant Smad1 or Smad1 domains also did not change the
endogenous expression of Smad4 in C3H10T1/2 and C3H10T1/2BMP2 cells. However, cells
with a BMP2 background showed a higher Smad4 mRNA level which was neither mimiced by
the Smad1 C domain nor was it inhibited by the Smad1 P domain.
The endogenous expression of anti-Smads was also investigated. Smad6 could not be
amplified by RT-PCR with the specific primers (Appendix RT-Smad6) in all the cell lines (data
not shown). Smad7 was expressed in all the monitored cells at roughly the same level (Fig
2.37). The recombinant expression of Smad1 wt, Smad1 C domain and P domain did not
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affect the expression level of  endogenous Smad7 in C3H10T1/2 cells and C3H10T1/2BMP2
cells. 
Fig. 2.37: RT-PCR analyses of the endogenous expression of Smad7 in C3H10T1/2 and C3H10T1/2BMP2 cells
expressing Smad1 wt, Smad1 C domain and P domain (after equalization of cDNAs). 1 µl cDNA stock
solution, 30 cycles at 60°C. x = RNA was lost during isolation.
Taken together, the expression of the murine endogenous Smad1-, Smad2-, Smad4- and
Smad7-gene was not regulated in C3H10T1/2 cells by BMP2 or recombinant Smad1. These
results imply that the endogenous Smad1-, Smad2-, Smad4- and Smad7-gene may not
contribute to the BMP2- or Smad1- dependent  osteogenic development in C3H10T1/2 cells.
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2.8 Transcriptional response assays
The morphological and genetic characterization of the C3H10T1/2 and C3H10T1/2BMP2 cells
recombinantly expressing Smad1 and its domains showed that wild type Smad1 and the Smad1
C domain are able to induce C3H10T1/2 cells or to stimulate C3H10T1/2BMP2 cells to
differentiate into osteoblasts. The Smad1 N domain and Smad1 P domain function as negative
regulators of this process. BMP-responsive promoters were used to investigate as to whether
or not this negative action on osteogenesis is reflected on the level of transcription. Following
promoters: 3TP-Lux, Msx-1, PTH/PTHrP receptor, JunB and a luciferase reporter were used
to investigate this possibility. 
A vector harboring 3TP-Lux promoter was stably transfected into C243 cells; in addition,
three vectors with the Msx-1 promoter constructs (from R. Raghow, USA), the PTH/PTHrP
receptor promoter constructs (from M. Karperien, Netherlands), the JunB promoter construct
(from P. Angel, Heidelberg) (-816/+28) which was subcloned into the pGL2-basic luciferase
vector, all these vectors were also routinely used for transient assays. The results of luciferase
assays were normalized with ß-galactosidase activity, therefore transient transfections were
done in the presence of a ß-galactosidase reporter under the control of a SV40 early promoter.
2.8.1 Construction of JunB (-816/+28) promoter-luciferase expression 
vector
Originally the JunB promoter region -816/+388 was in a Bluescript pSK vector. To investigate
the mechanism of activation of JunB promoter by BMP2, a JunB promoter-luciferase reporter
was constructed containing the JunB TATA box and transcription start site, and -816 bases
start site upstream sequences. The  BamH I site at +28 and the BamH I site in the vector
(+1927) were used for the restriction digestion. The pGL2-basic vector was also digested with
Bgl II in order to get a compatible ends.
2 Results
65
Fig. 2.38: pGL2-basic vector map.
Fig. 2.39:  Restriction digestion of JunB promoter (-816/+388) in pSK with BamH I and of luciferase reporter
vector pGL2-basic with Bgl II.
A: JunB promoter (-816/+388) in pSK digested with BamH I. 
    S = DNA standard (Lambda DNA/EcoR I + Hind III marker)
    J =  JunB promoter (-816/+388) in pSK
B: pGL2-basic digested with Bgl II.
    S = DNA standard (Lambda DNA/EcoR I + Hind III marker)
    P = pGL2-basic
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The ligation was carried out with Ready-To-Go T4 DNA ligase kit at 16°C overnight. High
voltage electroporation was performed for transformation. After minipreps of the clones,
restriction digestions were perfomed with EcoR I and Hind III respectively in order to identify
the postive clones with the right orientation of the insert (Fig. 2.40).
Fig. 2.40: Digestion of clone 4, 7, 10, 24 with EcoR I or Hind III.
A: Clones digested with EcoR I .
     S1 = DNA standard (Lambda DNA/EcoR I + Hind III marker)
B: Clones digested with Hind III.
     S2 = DNA standard (100 bp DNA ladder)
There are one EcoR I site and one Hind III site in the insert and so are there in the pGL2-basic
vector. If the insert was in the right orientation, after digestion with EcoR I or Hind III there
should be two fragments: about 5.0 kb/1.4 kb (for EcoR I digestion) and 6.4 kb/ 65bp (for
Hind III digestion); If the insert was in the wrong orientation, there would be two fragments of
about 5.8 kb/0.6 kb (for EcoR I) and 5.6 kb/ 0.8 kb (for Hind III). As shown in Fig. 2.40, the
inserts in clone Nr. 4, 7 and 10 were in the right orientation, the insert in clone Nr. 24 was in
the wrong orientation. The clone Nr. 4 was chosen as the JunB promoter-luciferase construct
for the later experiments.
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2.8.2 Transient transfections of the BMP-regulated promoter-luciferase constructs 
into eukaryotic cells
The cells were plated at a density of 5000 cell/cm2 into 12-well-plates 24 hours before
transient transfection. The transfections were performed with the Dosper Liposomal
Transfection Reagent kit (Chapter 5.5.6.2). For each well the transfection buffer included 1.5
µg expression vector for control or Smad1 domain DNAs, 0.5 µg promoter-luciferase
construct and 0.1 µg ß-galactosidase DNA. When increasing amounts of expression vectors
were transfected, total DNA was kept constant by addition of control vector pMT7T3. The
luciferase activity and ß-galactosidase activity assays were performed two days after transient
tranfections.
2.8.3 Luciferase assays of the promoter-luciferase constructs transfected cells
The transient transfected cells were isolated with the lysis buffer in ß-Galactosidase Reporter
Gene Assay Kit, because the lysis buffer is fully compatible with luciferase assay procedures.
The luciferase activity was measured with a luminometer. ß-galactosidase activity was
measured (Chapter 5.4.10.2) to determine the transfection efficiency in each assay, and the
luciferase activity was standardized in regard to the ß-galactosidase activity.
2.8.3.1 The ß-galactosidase expression vector dependent ß-galactosidase activity in 
transient assays
In order to use the ß-galactosidase as a mean to evaluate the transfection efficiency, it is
necessary to show that the amount of ß-galactosidase expression vector has a proportional
influence on the ß-galactosidase activity. Therefore, C3H10T1/2 cells were transiently
transfected with 0.1 or 0.2 µg ß-galactosidase expression vector in the presence of pMT7T3
vector (to keep the total DNA amount constant in each transfection). The cell lysates were
incubated at 50°C for 60 min. to reduce background counts. Then the protein concentration
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was measured with the Micro BCA Protein Assay Reagent kit (Pierce). It is demonstrated in
Fig. 2.41 that a relatively proportional relation exists between the amount of ß-galactosidase
expression vector and ß-galactosidase activity. So, in this range the ß-galactosidase activity
may be regarded as a reliable criterion of transfection efficiencies.
 
Fig. 2.41: The proportional relation between ß-galactosidase vector amount and ß-galactosidase activity. The
values were determined as mean ± S.E. (standard error) of three separate transfections.
2.8.3.2 Smad1 and its domains do not activate the p3TP-lux promoter-luciferase 
construct in murine C243 cells
The p3TP-lux luciferase reporter is a well-described and widely used artificial promoter
construct which was empirically designed to have maximal responsiveness to TGF-ß (Wrana et
al. 1992). p3TP-lux has a 31-nucleotide, AP1 site-containing region of the collagenase
promoter, concatemerized 5’ to an about 400-nucleotide region of the plasminogen activator
inhibitor type I (PAI-1) promoter followed by 70 bp of the adenovirus E4 promoter (Yingling
et al. 1997). Smad2, Smad3 and Smad4 have been shown to play some roles in potentiating
TGF-ß/activin stimulation of transcription of the p3TP-lux construct (Chen et al. 1996; Lagna
et al. 1996). To test whether Xenopus Smad1 has a stimulationary effect on p3TP-lux reporter
activity, the murine C243 cells with the stable incorporation of 3TP-Lux vector
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(C243-p3TP-lux) were transiently transfected with Smad1 domains and luciferase activity was
then measured.
Fig. 2.42: The influence of recombinant Smad1 and Smad1 domains on p3TP-lux luciferase activity (after
normalization with ß-galactosidase activity). The values were determined as mean ± S.E. (standard error) of
three separate transfections.
1. C243-p3TP-lux cells
2. C243-p3TP-lux/control vector
3. C243-p3TP-lux/wild type Smad1
4. C243-p3TP-lux/Smad1 C domain
5. C243-p3TP-lux/Smad1 (C+P) domain 
6. C243-p3TP-lux/Smad1 N domain
7. C243-p3TP-lux/Smad1 (N+P) domain 
8. C243-p3TP-lux/Smad1 P domain
9. C243-p3TP-lux/Smad1 (C+N) domain 
Fig. 2.42 showed that recombinant Smad1 and its domains have neither stimulated nor
inhibited the luciferase activity of the p3TP-lux in C243 cells. This may be explained by the
fact that the C243 cell line is not a TGF-ß or BMP2 responsive cell line, therefore the
BMP-responsive procedures were then characterized in the mesenchymal progenitors
C3H10T1/2 cells. 
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2.8.3.3 The influence of Smad1 domains on the JunB promoter (-816/+28)-luciferase 
activity
The product of the JunB gene is a member of the AP-1 family of trancription factors that
activate transcription by binding to TPA responsive elements (TREs) within the promoter of
the target genes (Angel et al. 1987). AP-1 components are immediately early gene products
whose expression is rapidly induced by a variety of extracellular stimuli and are encoded by the
Fos and Jun families of genes that have been shown to be involved in growth control and
differentiation (Angel and Karin 1991). JunB differs in biological properties from its homologs
and appears to be a negative regulator of AP-1 function (Chiu et al 1989). The action of JunB
as a negative regulator of TRE responce elements is consistent with its induction by negative
regulators of cell growth including TGF-ß as well as activin and BMP2/4 (de Groot and
Kruijer 1991; Li et al. 1990; Hashimoto et al. 1993; Chalaux et al. 1998). Developmental
studies performed in vitro and in vivo implicate that the Fos and Jun family of transcription
factors play a role in regulation of bone tissue formation (Johnson et al. 1992; Reimold et al.
1996). From all AP-1 transcription factors studied, only JunB is highly induced at early times
after BMP2 or TGF-ß addition (Chalaux et al. 1998). The JunB is not affected by the protein
synthesis inhibitor cycoheximide suggesting the transacting factors required for transcription
pre-exit in the cell, and the Smad family may be the direct mediators of this JunB
transcriptional activation (Chalaux et al. 1998).
The JunB promoter (-816/+28)-luciferase construct was transiently transfected into
C3H10T1/2 and C3H10T1/2BMP2 cells to test whether the BMP2 background leads to
enhancing transcriptional activity directed by the JunB promoter in C3H10T1/2 cells.
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Fig. 2.43: The luciferase activity mediated by the JunB promoter (-816/+28) construct in C3H10T1/2 and
C3H10T1/2BMP2 cells (after normalization with ß-galactosidase activity). The values were determined as mean ±
S.E. (standard error) of three separate transfections.
The JunB promoter-luciferase activity in a BMP2 background is about 2-fold enhanced in
comparison with in control C3H10T1/2 cells (Fig. 2.43). Because NIH3T3 cells exhibit similar
results but by far better transfection characteristics than C3H10T1/2 cells, more detailed
analyses were performed in these cells. Whether the BMP signal mediator Smad1 has an effect
on the JunB promoter activity was then investigated. In this experiments NIH3T3 cells were
transfected with 1.6 µg pMT7T3; 0.8 µg expression vector for Smad1 C domain and 0.8 µg
pMT7T3; 0.8 µg expression vector for Smad1 P domain and 0.8 µg pMT7T3; 0.8 µg
expression vector for Smad1 C domain and 0.8 µg expression vector for Smad1 P domain.
The luciferase activity assay indicated that expression of the Smad1 C domain leads to
enhanced JunB promoter activity about 7-fold. The cells transfected with Smad1 P domain
also increased the promoter activity 2-fold. The JunB promoter dependent luciferase activity in
NIH3T3 cells cotransfected with Smad1 C domain and Smad1 P domain was higher than the
transfection of the P domain alone but significantly lower than C domain tranfected cells (Fig.
2.44) consistent with the earlier finding that the Smad1 P domain represses the Smad1 C
domain-dependent stimulation of transcription.
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Fig. 2.44: The influence of Smad1 C domain, P domain, and  C domain + P domain on JunB promoter
(-816/+34)-luciferase activity (after normalization with ß-galactosidase activity). The values were determined
as mean ± S.E. (standard error) of three separate transfections.
2.8.3.4 The influence of Smad1 domains on the PTH/PTHrP receptor 
promoter-luciferase constructs activity
The PTH/PTHrP receptor gene expression is obviously regulated by Smad1 wild type and
Smad1 C domain construct, while the Smad1 P domain abolished the PTH/PTHrP receptor
expression in both C3H10T1/2BMP2 cells and C3H10T1/2-Smad1 C cells (Chapter 2.3.2). So it
is likely that Smad1 might induce transcriptional activation of PTH/PTHrP receptor gene.
In this regard the PTH/PTHrP receptor promoter-luciferase constructs were kindly supplied by
M. Karperien, Leiden, Netherlands. Three of the PTH/PTHrP receptor promoter-luciferase
constructs were tested in our system. pLuc U1 2.9: this construct contains 2.9 kb upstream
sequences (Hind III/BamH I) of the downstream P2 promoter; pLuc S 3.9: this construct
contains a downstream intron between exon U1 and S, and is otherwise identical to pLuc U1
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2.9; pTK 0.6 kb: the 0.6 kb promoter fragment (KpnI/XbaI) was cloned in front of the
heterologous minimal TK-promoter in pTK Luc vector (Fig. 2.45).
Fig. 2.45: Diagram of the PTH/PTHrP receptor promoter containing luciferase reporters.
Fig. 2.46: The influence of Smad1 domains on luciferase activity directed by the PTH/PTHrP receptor
promoter (pLuc U1 2.9) (after normalization with ß-galactosidase activity) in NIH3T3 cells. The values were
determined as mean ± S.E. (standard error) of three separate transfections.
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1: NIH3T3/pMT7T3
2: NIH3T3/Smad1 C domain 
3: NIH3T3/Smad1 wild type
4: NIH3T3/Smad1 P domain
5: NIH3T3/Smad1 N domain
Fig. 2.47: The influence of Smad1 domains on luciferase activity directed by the PTH/PTHrP receptor
promoter (pLuc S 3.9) (after normalization with ß-galactosidase activity) in NIH3T3 cells. The values were
determined as mean ± S.E. (standard error) of three separate transfections.
1: NIH3T3/control vector
2: NIH3T3/Smad1 C domain 
3: NIH3T3/Smad1 wild type
4: NIH3T3/Smad1 P domain
The luciferase activity of Smad1 domains transient transfected cells (Fig. 2.46, 2.47) indicated
that the PTH/PTHrP receptor promoter construct pLuc U1 2.9 and 3.9 activity are not
influenced by Smad1 wild type and its domains. Consistent with this result, we learned after
this experiments that sequences about 7000 bp upstream of U1 are necessary for regulated
activativities in rat osteosarcoma ROS17/2.8 cells (M. Karperien, personal communication).
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While the luciferase activties of PTH/PTHrP receptor promoter pTK 0.6 were significantly
induced about 10-fold and 6-fold in NIH3T3 cells transfected with wild type Smad1 and
Smad1 C domain (Fig. 2.48). Smad1 N domain and Smad1 P domain have also stimulated the
promoter activity. The promoter activity of cells cotransfected with Smad1 P domain and
Smad1 C domain was significantly lower than the cells transfected with Smad1 C domain
alone. This implies that the 0.6 kb promoter fragment is BMP- or Smad1-responsive element,
whose activity is normally silenced by the other regions of the PTH/PTHrP receptor promoter.
Fig. 2.48: The influence of Smad1 and its domains on PTH/PTHrP receptor promoter pTK 0.6 directed
luciferase activity (after normalization with ß-galactosidase activity) in NIH3T3 cells. The values were
determined as mean ± S.E. (standard error) of three separate transfections.
1: NIH3T3/pMT7T3
2: NIH3T3/Smad1 wt
3: NIH3T3/Smad1 C domain
4: NIH3T3/Smad1 N domain 
5: NIH3T3/Smad1 P domain 
6: NIH3T3/Smad1 C domain +Smad1 P domain
2.8.3.5 The influence of Smad1 domains on the Msx-1 promoter-luciferase constructs 
activity 
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Msx genes are vertebrate homologues of Drosophila msh (muscle segment homeobox) gene
and  it has been reported that they are BMP responsible genes (reviewed by Davidson 1995).
Direct evidence has been found that addition of BMP2 or BMP4 can induce the expression of
both Msx-1 and Msx-2 in tooth mesenchymal explants (Vainio et al. 1993). The timing of
expression and embryonic distribution of Msx1 parallel that described for BMPs. Moreover, it
was demonstrated that Msx1 can mimic the activities of BMPs: overexpression of Msx1 in
early Xenopus embryos leads to ventralization (Suzuki et al. 1997). The effect of Smad1 on
the downstream factors of BMP was investigated in Msx1 promoter-luciferase assay level. We
obtained Msx1 luciferase reporter constructs from R. Raghow, Memphis.
Fig. 2.49: Maps of Msx1 promoter fragments in pGL2-basic vector.
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Three different length Msx1 promoter fragments (-1280/+102; -884/+102: and -164/+102)
have been cloned into pGL2-basic vector (Fig. 2.49). They were transiently transfected into
C3H10T1/2 and C3H10T1/2BMP2 cells to test whether or not BMP2 has an effect on Msx1
promoter-luciferase activity.
Fig. 2.50: The activity of three Msx1 promoter-luciferase constructs in C3H10T1/2 and C3H10T1/2BMP2 cells
(after normalization to ß-galactosidase activity). The values were determined as mean ± S.E. (standard error) of
three separate transfections.
1, 4, 7: C3H10T1/2 cells transfected with three Msx1 promoter constructs
2, 5, 8: C3H10T1/2BMP2 cells transfected with three Msx1 promoter constructs
As shown in Fig. 2.50, all three Msx1 promoter-luciferase constructs were all stimulated by
BMP2, though at different efficiency. In C3H10T1/2BMP2 cells the Msx1-164/+102, the
Msx1-844/+102, and the Msx1-1280/+102 promoter-luciferase activity are respectively 3-fold,
1.6-fold and 1.9-fold higher than in C3H10T1/2 cells. The optimal stimulation of BMP2 on
luciferase activity was observed in Msx1-164/+102 promoter region, so additional experiments
were performed with this promoter-luciferase construct .
BMP2 seems to exert a 3-fold stimulation on the Msx1-164/+102 promoter-luciferase activity.
The effect of the BMP2-signal mediator Smad1 and its domains on the Msx1-164/+102
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promoter-luciferase was then tested in cotransfection experiments in the parental C3H10T1/2
cells. In this experiments  control vector pMT7T3, wild type Smad1, Smad1 C domain, Smad1
N domain and Smad1 P domain in the presence of Msx1-164/+102 promoter-luciferase
construct and ß-galactosidase expression vector were transiently transfected into C3H10T1/2
cells. The results of luciferase activity was normalized for ß-galactosidase activity.
Fig. 2.51: The influence of recombinant Smad1 wild type, C domain, N domain and P domain on
Msx1-164/+102 promoter-luciferase construct activity in C3H10T1/2 cells (after normalization with
ß-galactosidase activity). The values were determined as mean ± S.E. (standard error) of three separate
transfections.
1, 2, 3, 4, 5: C3H10T1/2 cells were transfected with expression vector pMT7T3, wild type Smad1, C domain,
N domain and P domain.
The recombinant Smad1 and Smad1 C domain, N domain and even the  P domain have
stimulated the luciferase activity under the control of Msx1-164/+102 promoter-luciferase
constructs (Fig. 2.51). The cells transfected with Smad1 C domain construct showed the
highest activity. Interestingly, also the Smad1 P domain stimulates luciferase activity although
lower in comparison with the other constructs. 
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The stimulation of Smad1 C domain on Msx1-164/+102 promoter-luciferase activity was also
confirmed in NIH3T3 cells (Fig. 2.52). The NIH3T3 cells have better efficiencies in transient
transfections and showed a similar effect as C3H10T1/2 cells after being transfected with
Smad1 domains. Therefore, the later transient transfections were normally carried out in
NIH3T3 cells. The Smad1 C domain and P domain have both stimulated the luciferase activity,
Smad1 C domain showed about 10-fold stimulation, and Smad1 P domain has only about
1.5-fold stimulation compared with the control vector. Smad1 C domain transfected cells have
about 6-fold higher luciferase activity in comparison with  Smad1 P domain transfected cells.
Fig. 2.52: The influence of Smad1 C domain and P domain on  Msx1-164/+102 promoter activity in NIH3T3
cells (after normalization with ß-galactosidase). The values were determined as mean ± S.E. (standard error) of
three separate transfections.
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Fig. 2.53: The influence of Smad1 domain constructs on Msx1-164/+102 promoter activity in NIH3T3 cells
(after normalization with ß-galactosidase). The values were determined as mean ± S.E. (standard error) of
three separate transfections.
1: NIH3T3/control vector
2: NIH3T3/wild type Smad1
3: NIH3T3/Smad1 C domain
4: NIH3T3/Smad1 P domain 
5: NIH3T3/Smad1 C + ½ Smad1 P domain
6: NIH3T3/Smad1 C + 1 Smad1 P domain
As shown in Fig. 2.53 the interference between Smad1 C domain and Smad1 P domain was
investigated in NIH3T3 cells. 2.2 µg total DNA was used for each transfection, of which 0.5
µg was Msx1-164/+102  promoter construct, 0.1 µg was ß-galactosidase vector, the
remaining 1.6 µg were control vector or Smad1 domains in an expression vector. Panel 2, 3
and 4 represent the luciferase activity of NIH3T3 cells transfected with 0.8 µg expression
vector for Smad1 wild type, Smad1 C domain, Smad1 P domain, Smad1 (C+N) domain,
respectively, and 0.8 µg pMT7T3 vector DNA. Panel 5 shows the luciferase activity of cells
transfected with 0.8 µg expression vector for Smad1 C domain + 0.4 µg expression vector for
Smad1 P domain + 0.4 µg pMT7T3 vector DNA. Panel 6 shows the luciferase activity of cells
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transfected with 0.8 µg expression vector for Smad1 C domain + 0.8 µg expression vector for
Smad1 P domain.
Smad1 wild type, Smad1 C domain, and Smad1 P domain showed an about 4-fold, 3-fold, and
2-fold induction in comparison with control vector. Panel5 and 6 documented the
dose-dependent interference of Smad1 P domain with Smad1 C domain dependent biological
activities.
In total, the experiments document that one can substentiated with BMP-responsive promoters
the histological and genetic analyses of Smad signaling-mediators in mesenchymal progenitors
C3H10T1/2 cells.
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3 Discussion
3.1 The effects of overexpression of Xenopus Smad1 on osteogenic, 
chondrogenic and adipogenic development in C3H10T1/2 and 
C3H10T1/2BMP2 cells 
C3H10T1/2 cells represent a relatively early stage of mesenchymal cell determination with
the ability to differentiate into osteoblasts, adipocytes and chondrocytes. Their
multipotential nature and their responsiveness toward TGF-ß and BMP treatment make this
cell line a useful model system to explore the involvement of factors in various
mesenchymal differentiation processes. A series of studies revealed that BMP2 has the
ability to stimulate osteogenesis in predetermined osteogenic cell lines and to induce
osteogenesis in undetermined mesenchymal progenitor cell line (Chen et al. 1991; Tokuwa
et al. 1991; Thies et al. 1992). In C3H10T1/2 cells, BMP initiates development into the
osteogenic, chondrogenic and adipogenic lineage (Ahrens et al. 1993; Wang et al 1993). 
Smad1´s function, especially the function of its three domains, was investigated in
BMP2-dependent osteo/chondrogenic mesenchymal differentiation system. The Xenopus
recombinant Smad1 and its domains were stably transfected into the murine, mesenchymal
progenitor cell line C3H10T1/2 and C3H10T1/2BMP2 cells (Chapter 2.1.2 to 2.1.4). The
Xenopus Smad1 is highly identical with murine Smad1, even the P domains shares a 89.1%
identity with the corresponding sequence in murine Smad1 (Fig. 3.1).
The osteogenic differentiation potential of C3H10T1/2 cells was assessed by alkaline
phosphatase staining (Fig. 2.7; 2.8; 2.9; 2.10) and genetic analyses of marker genes typical
or specific for osteogenesis, including: osteocalcin (Fig. 2.13), PTH/PTHrP receptor (Fig.
2.14), collagen I (Fig. 2. 15), CBFA1 (Fig. 2.16), osteopontin (Fig. 2.17), and osteonectin
(Fig. 2.18); the chondrogenic differentiation potential of C3H10T1/2 cells was assessed by
Alcian Blue staining (Fig. 2.11) and genetic analyses of marker genes typical or specific for
chondrogenesis: collagen II (Fig. 2.19) and FGFR-3 (Fig. 2.20); The adipogenic potential
of C3H10T1/2 cells was identified morphologically (Fig. 2.4; 2.5, 2.6) and by the adipoQ
gene expression (Fig. 2. 21), which is specific for adipogenesis (Chapter 2.2 and 2.3).
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Fig. 3.1:  Protein sequence alignment between Xenopus Smad1 and murine Smad1.
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In this investigation we show that  the BMP-2 dependent signaling molecule Smad1 or its
biological active domain (C domain) induced the alkaline phosphatase avtivity (Fig. 2.9)
and the expression of osteogenesis marker genes such as osteocalcin (Fig. 2.13),
PTH/PTHrP receptor (Fig. 2.14) and collagen I (Fig. 2.15) in C3H10T1/2 cells. In
addition, in C3H10T1/2BMP2 cells, the BMP2 dependent activation of alkaline phosphatase
(Fig. 2.10), osteocalcin (Fig. 2.13), PTH/PTHrP receptor (Fig. 2.14) and collagen I gene
(Fig. 2.15) was enhanced by Smad1 or its bological active domains. Therefore, on the basis
of histological and genetic analyses, Smad1, as the BMP2 signaling transducer, was
demonstrated to play an important role in inducing the C3H10T1/2 cells differentiation into
osteogenic lineage.
Chondrocytes were identified in C3H10T1/2 cells expressing BMP2/BMP4 on the basis of
Alcin Blue staining (Ahrens et al. 1993). Whether Smad1 or its domains mediated the
BMP2 dependent chondrogenesis was investigated in C3H10T1/2 and C3H10T1/2BMP2
cells. Chondrocytes were not detected in C3H10T1/2 cells expressing recombinant Smad1
or its domains by Alcian Blue staining (Fig. 2.11), which implies that the recombinant
Smad1 and its domains are not sufficient to initiate the development of C3H10T1/2 cells
into chondrogenic lineage. Chondrocyte-formation was observed in C3H10T1/2BMP2 cells
expressing Smad1 wild type, C domain or P domain, however, at a level comparable with
that of control C3H10T1/2BMP2 cells. Furthermore, the expression of chondrogenic marker
genes, such as collagen II or FGFR-3 was not regulated by recombinant Smad1 or Smad1
domains (Chapter 2.3.7 and 2.3.8). Therefore, it can be anticipated from these results that
the chondrogenic potential of C3H10T1/2BMP2 cells was neither stimulated by
overexpression of Smad1 biological active domains nor inhibited by overexpression of the
Smad1 P domain, the negative regulator for osteogenesis. BMP2-dependent
chondrogenesis appears to be mediated by other signaling molecules other than Smad1.
Smad5, Smad8, or mediators of the MAP-kinase pathway, such as TAK1, or TAB1 could
exert the induction of BMP2-induced chondrogenic development.
The role of BMPs in adipogenesis is less clearly defined since several studies indicate a
BMP-dependent stimulation while other reports describe an inhibition of adipogenesis in
differentiation systems like those established from bone marrow stroma cells (Gimble et al.
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1995). In BMP2 expressing C3H10T1/2 cells adipocytes were observed during 15-days of
cultivation (Ahrens et al. 1993). However, the expression of adipoQ in C3H10T1/2 and
C3H10T1/2BMP2 cells expressing recombinant Smad1 or its domains, combined with the
erratic appearance of adipocytes in the above cell lines (Fig. 2.5 and 2.6), implied that
BMP2 contributes to adipoQ expression and the number of adipocytes in C3H10T1/2 cells.
However, other factors, in addition to Smad1, might play more important roles in the
BMP2-dependent adipogenesis.
The effect of recombinant expression of Xenopus Smad1 and its domains on
BMP2-dependent osteogenesis in C3H10T1/2 cells was not due to up/down-regulation of
the endogenous R-Smads, Co-Smad or Anti-Smads, because overexpression of Smad1 has
no obvious influence on the endogenous expression level of Smad1, Smad2, Smad4 and
Smad7 (Fig. 2.34; 2.35; 2.36; 2.37). In addition, the RT-PCR analyse with Smad4 suggests
that the endogenous level of Smad4 is sufficient for co-operation with the overexpressed
Smad1 to carry out the nuclear functions.
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3.2 The different roles of the Smad1 N terminal domain, proline-rich 
linker region and C terminal domain in osteogenic development of 
C3H10T1/2 cells
As described above, except CBFA1 and the osteopontin and osteonectin genes, the
osteogenetic marker genes, including alkaline phosphatase, PTH/PTHrP receptor, collagen
I gene were all regulated by Smad1 and its domains in C3H10T1/2 and C3H10T1/2BMP2
cells (Chapter 2.2; 2.3). In addition, the three domains of Smad1 were shown to play
different roles in this process (Table 3.1). 
******CBFA1
↑↑↓↓*↑Osteocalcin
******Osteonectin
***↑↓↓Osteopontin
*↑↓↓↓↑PTH/PTHrP receptor
↑↑↓↓↓↓Collagen I
↑↑↑↓*↓*Alkaline Phosphatase 
C
C3H10T1/2BMP2
C
C3H10T1/2
P
C3H10T1/2BMP2
P
C3H10T1/2
N
C3H10T1/2BMP2
N
C3H10T1/2
                   Domain
        Effect
Gene
Table 3.1: The role of recombinant Smad1 N domain, P domain, and C domain in the differentiation of
C3H10T1/2/C3H10T1/2BMP2 cells into osteogenic lineage. ↑ = stimulation or induction; ↓ = repression or
reduction; * = no effect.
The Smad C domain has been shown to have effector function in transcriptional assays (Liu
et al. 1996) and Xenopus mesoderm forming assays (Baker and Harland 1996). Mutations
of carboxy-terminal serines prevents several Smad1 activation events: association with
Smad4, accumulation in the nucleus and gain of transcriptional activity (Macias-Silva et al.
1996). All these indicate that the C domain of Smad proteins has played the key role in
Smads-mediated signal transduction. In our experiments, the Smad1 C domain induced (in
C3H10T1/2 cells) or stimulated (in C3H10T1/2BMP2 cells) alkaline phosphatase activity and
the expression of osteogenic marker genes: osteocalcin, PTH/PTHrP receptor, and collagen
I (Fig. 2.9, 2.10, 2.13, 2.14 and 2.15), substantiating the above conclusions. However the
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point mutant Smad1G419S has been shown to interfere with BMP-mediated phosphorylation
of the C-terminal domain and to exert dominant negative functions (Pamela et al. 1995).
Here expression of this Smad1 mutation repressed the BMP2-dependent alkaline
phosphatase activity, but not in a dominant-negative way (Fig. 2.8), demonstrating that
probably also other molecules than Smad1 are involved in osteo/chondrogenic
development.
The sequence-specific DNA-binding activity of the Drosophila Mad N domain directed
transcriptional activation in response to the Drosophila BMP-2 homologue
Decapentaplegic (DPP) (Kim et al. 1997). This may provide an explanation for the
stimulatory effect of Smad1 N domain on the PTH/PTHrP receptor and the osteocalcin
gene expression in C3H10T1/2 cells (Fig. 2.14 and 2.13). On the other hand, we also
observed that Smad1 N domain is a negative regulator of the alkaline phosphatase activity
in C3H10T1/2BMP2 cells and also repressed collagen I expression in both cell lines (Fig. 2.10
and 2.15). It would be reasonable to hypothesize that in these cases the Smad1 N domain
specific binding sites are not sufficient for transcriptional activation. 
For the P-domain it has been shown that it contributes to the maximal activity of the Smad1
C domain (Meersseman et al. 1997). Also, the DNA-binding activity of the N domain can
be enhanced by the linker region (Kim et al. 1997). We have observed that the stimulation
of the osteocalcin, PTH/PTHrP receptor, and collagen I gene expression by Smad1 (C+P)
domain and (N+P) domain in C3H10T1/2 cells was higher than by Smad1 C domain and N
domain alone (Fig. 2.13, 2.14 and 2.15). This  implies that the P domain exerts a biological
activity. 
The P domain contains several MAPK sites, which can be phosphorylated by the MAP
kinase after cell stimulation by EGF, and therefore interferes with nuclear localization of
Smad1 and transcriptional activation (Kretzschmar et al. 1997b). But this fact can not
explain why the overexpression of the Smad1 P domain interferes with BMP2-induced
alkaline phosphatase activity and blocks the expression of osteocalcin and PTH/PTHrP
receptor gene in C3H10T1/2BMP2 cells (Fig. 2.10; 2.13 and 2.14) by a dominant negative
effect. In addition, Smad1 P domain also reduced the collagen I expression in parental
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C3H10T1/2 cells and C3H10T1/2BMP2 cells (Fig. 2.15B). In contrast, Smad1 P domain
stimulates the osteopontin expression in C3H10T1/2 cells (Fig. 2.17) and mimics the
BMP2/TGF-ß down-regulation of PEX in C3H10T1/2 cells (Fig. 2.32). 
The dose-dependent inhibition of the P domain on alkaline phosphatase activity and the
expression of two osteogenetic marker genes: osteocalcin and PTH/PTHrP receptor in
C3H10T1/2-Smad1 C cells (Fig. 2.23, 2.24, 2.25), combined with the data that
BMP2-dependent osteogenesis was also inhibited by Smad1 P domain (Chapter 2.3) lead to
the conclusion that Smad1 P domain inhibited the BMP2- and Smad1 C domain-induced
osteogenesis. The similar inhibitory effect was not observed in C3H10T1/2BMP2 cells
expressing Smad3 P domain: overexpression of Smad3 P domain in C3H10T1/2BMP2 cells
did not affect the expression of PTH/PTHrP receptor, osteocalcin and alkaline phosphatase
gene (Fig. 2.30; 2.31; 2.29). So the P domain-dependent inhibition on BMP2- or Smad1 C
domain-induced osteogenesis seems relatively specific for Smad1 P domain.
Fig. 3.2 shows the similarity of the protein sequences between Smad1 and Smad3. The N
domain and C domain are conserved, but the sequences between the two P domains show
little similarity. In addition, a stretch 31-amino acid is missing in the P domain of Smad3
when compared with the P domain of Smad1.
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Fig. 3.2: The Protein sequence alignment between Smad1 and Smad3.
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How Smad1 P domain exerts its function is unclear, but the studies from Lechleider and
collegues with Smad4 indicates that there is a 47-amino acid SAD (Smad Activation
Domain) within the COOH-terminal portion of the proline-rich linker region of Smad4
which is necessary for this molecule to transduce signaling responses downstream from
TGF-ß receptors. In the absence of ligand, the N domain of Smad4 may obscure the SAD
which locates at the extreme COOH-terminal of the linker region, either by direct blockade
of this region or by conformational interference. Following ligand-activation, there may be
unfolding of the molecular structure resulting in exposure of the SAD, allowing it to
interact with other signaling partners (de Caestecker et al. 1997). Although the linker
region of Smad4 shows minimal sequence similarity with those of the other Smad family
members, it is still possible that the P domain of Smad1 could also possess a SAD-like
domain, which is blockaded in the absence of ligand and is activated after ligand mediated
signaling. This potential SAD-activity would be present in overexpressed recombinant P
domains.
The function of SAD-like domains is interacting with signaling molecules. In the cells
overexpressing Smad1 P domains, the Smad1 P domains could bind to Smad1 C domains
through SAD-like domains. This binding interferes with the multimerization of Smad1 C
domains, therefore Smad1 C domains could neither form heteropolymers with Smad4 nor
enter into the nucleus to exert its nulear functions (Fig. 3.3 -I).  This appears to be a
relatively Smad1 specific event since the overexpression of Smad3 P domain does not
interfere with the nuclear functions of Smad1 C domains (Fig. 3.3-II).
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Fig. 3.3:  Signal transduction in cells overexpressing (I) Smad1 P domain; (II) Smad3 P domain. 
The osteocalcin gene has been reported to have a CBFA1 binding site in 5’ flanking region
and is induced by the transient expression of CBFA1 in MC3T3-E1 cells and C3H10T1/2
lls (Ducy et al. 1997). In addition, CBFA1 most likely regulates collagen I gene expression
(Komori and Kishimoto 1998). In the present study, the results showed that the expression
of CBFA1 in C3H10T1/2 and C3H10T1/2BMP2 cells recombinantly expressing Smad1
domains was kept in the same level in comparison with control cells (Fig. 2.16), whereas
the expression of osteocalcin and collagen I was obviously regulated in above cell lines
(Fig. 2.13 and 2.15). These data correlate well with these studies that BMP2 does not
enhance the CBFA1 expression although BMP7 (Ducy et al 1997) or BMP4/BMP7
heterodimer (Tsuji et al 1998) specifically enhances expression of CBFA1 in C3H10T1/2
cells, MC3T3-E1 cells, and C2C12 cells. This implies that the essential factor for osteoblast
differentiation-CBFA1 is not up-regulated by BMP2 or the Smad1 signal transduction.
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3.3 The transcriptional assays substantiated the genetic and 
histological analyses of Smad1 signaling mediator 
TGF-ß family members mediate their cellular actions at least in part by controlling the
transcription of target genes. Investigation of transcriptional actions by Smads has revealed
a complex pattern involving multiple proteins and diverse response promoter elements. For
instance, the C domain fused to a heterologous DNA binding domain, was found to induce
a transcriptional response (Liu et al. 1996; Meersseman et al. 1997). In addition, Smad2
and Smad4 participate in the activin-mediated transcriptional induction of the Xenopus
Mix-2 promoter where they act as co-activators via an interaction with the FAST-1
DNA-binding factor (Chen, X. et al. 1996; 1997). Furthermore, the Drosophila Mad,
deleted in the conserved MH2 domain, binds directly to GC-rich regions of various
enhancers (Kim et al. 1997).
Recently, the studies of this complex mechanism of transcriptional regulation of TGF-ß
responsive genes lead to precise location of the Smad binding sites in promoter sequences,
an 8 bp palindromic DNA sequence 5’-GTCTAGAC-3’ was identified as the Smad binding
element (SBE) through PCR-based random oligonucleotide selection process. The 4 bp site
5’-GTCT-3’ in SBE represents the minimal binding sequence, was termed as Smad box
(Zawel et al. 1998). Almost at the same time, it is reported that the identification of the
SBEs composed of the sequences 5’-CAGACA-3’ in the promoter of the JunB gene (Jonk
et al. 1998). This Smad3/Smad4 binding sequences were also identified within the promoter
of the human plasminogen activator inhibitor-1 (PAI-1) gene and was termed CAGA boxes
(Dennler et al. 1998). The SBE is only efficiently bound by bacterially produced Smad3 and
Smad4, but not Smad2 and BMP signaling Smad1 and Smad5 proteins (Dennler et al.
1998; Jonk et al. 1998). It is possible that Smad1 and Smad5 require additional proteins for
high affinity binding to these sequences. Alternatively, in contrast to Smad3, these Smads
may associate with their target sequence only through Smad4 (Jonk et al. 1998). The
full-length Smad4 protein possessed a direct DNA-binding activity on the CAGA box
(Dennler et al. 1998) suggesting a mechanism other than only the N domain of Smad1 is
able to bind DNA.
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The two modes of Smad function, as direct DNA binding proteins and as transcriptional
coactivitor proteins, broaden the possible range and diversity of Smad promoter targets. In
certain contexts, the interaction of specific Smad heteromers with specific transcription
factors may lead to promoter activation. In this context, the DNA binding function of the
Smads becomes dispensable. While other promoter contexts may require the DNA binding
function of the Smads to target and activate the promoter, as is the case with Mad and the
vestigial promoter (Yingling et al. 1998).
We investigated the individual effect of Smad1 and its domains on the activity of
BMP-responsive gene promoter-luciferase constructs, such as Msx1, PTH/PTHrP receptor,
and JunB. Our studies show that BMP2 background stimulates the activity of three Msx1
promoter luciferase constructs in C3H10T1/2 cells. Among the Smad1 wt and its domains,
the Smad1 C domain maximally stimulated the Msx1 -164/+102 promoter luciferase
activity (Fig. 2.51, 2.52, 2.53), which implies that the Smad1 regulates the Msx1
transcription not necessarily by the DNA binding activity of Smad1 N domain, but by the
transcriptional activity of Smad1 C containing domains. Because the DNA binding activity
of Smad C domain has not been reported, it is therefore reasonable to speculate that the
Smad1 C domain or Smad1 wild type might form a complex with additional proteins,
possibly with Smad4, which alone is able to bind DNA in vitro. This DNA binding ability is
likely to be regulated or modified by association with its Smad partners in response to
exogenous signals under physiological conditions (Yingling et al. 1997), which then bind to
the specific DNA sequence in the Msx1 -164/+102 promoter region and activate its
transcription. 
The Smad1 wild type in our studies was also able to stimulate the Msx1 -164/+102 and
PTH/PTHrP receptor promoter luciferase activity (Fig.  2.51; 2.53; 2.48). This result is in
contrast with the very weak induction on the LacZ reporter expression by the Smad1 wild
type in Hela cells (Meersseman et al. 1997), but consistent with the transcriptional activity
of Smad1 full length induced by BMP treatment (Liu et al. 1996) and activation of JunB
transcription in vivo by Smad1 and Smad4 (Jonk et al 1998) .
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Interestingly, also the Smad1 P domain stimulated the promoter luciferase activity in
comparison with the control vector. This phenomenon was not only observed in the Msx1
-164/+102 promoter assay (Fig. 2. 51; 2.53) but also in the JunB (Fig. 2.44) and
PTH/PTHrP receptor (pTK 0.6) (Fig. 2. 48) promoter assay. This observation is consistent
with a weak but detectable transactivatory activity of the P domain of Smad1 (Meersseman
et al. 1997). In combination with C domain, however, the P domain exerts a clear inhibitory
effect.
The fact that Smad1 P domain interferes with the stimulation of Smad1 C domain on the
promoter luciferase activity of Msx1 -164/+102, JunB, and PTH/PTHrP receptor (pTK0.6)
(Fig. 2.53, 2.44, 2.48) raises the possibility that Smad1 P domain could form a complex
with Smad1 C domain, the complex might be unable to enter into the nucleus and therefore
the P domain would weaken the transcriptional stimulation of the Smad1 C domain on the
BMP-responsive genes.
The PTH/PTHrP receptor promoter pTK0.6 luciferase activity was stimulated by the
Smad1 wild type and C domain  in our assays ( Fig. 2.48), suggesting that a Smad1
responsive element exists in this promoter region. The activity of this 0.6 kb promoter
fragment, however, could be silenced by other regions of the promoter, since the
PTH/PTHrP receptor promoter luciferase constructs pLuc S3.9 and pLuc S2.9 were not
regulated by the Smad1 domains. 
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3.4 The model for signaling cascades of BMP-mediated 
osteo-/chondrogenic development in C3H10T1/2 cells
Based on our results, a model for signaling cascades in BMP-mediated osteo/chondrogenic
development in C3H10T1/2 cells is presented (Fig. 3.4). The BMPs exert their functions
through the association with type I and type II receptors. BMP2/BMP4 bind two human
type I receptors, Alk3 and Alk6 (Lin et al. 1992), which have also been termed BMP
receptor type IA and type IB (BMPR-IA and BMPR-IB) (ten Dijke et al. 1994). BMPR-IA
is predominantly responsible for the BMP-dependent osteo/chondrogenesis. BMPR-IA
seems to mediate induction of osteogenesis through the signaling mediator Smad1, while
the chondrogenic induction could be via the Smad5, Smad8 or MAPK signaling pathway
(Ph D thesis, Christian Kaps).
Fig. 3.4: Signaling cascades for BMP-mediated osteo/chondrogenic development in C3H10T1/2 cells. *
based on investigations of Christian Kaps in the laboratory.
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 4 Summary
The bone morphogenetic proteins (BMPs) belong to the transforming growth factor ß
(TGF-ß) superfamily. They regulate biological processes not only in bone morphogenesis, but
also the development of all organs and tissues, as well as in the establishment of the basic
embryonic body plan. The Smad-family members have been characterized recently as
important signaling mediators for TGF-ß-related factors. Smad1, Smad5 and Smad8 have been
identified as BMP signal transducers. The aim of this research was elucidate the functions of
the three domains: the N-terminal domain, the C-terminal domain and the proline-rich linker
domain of Smad1, especially the function of the less conserved proline-rich linker region, in
the mesenchymal differentiation processes, particularly in regard to osteo-/chondrogenic
development. For this purpose eukaryotic expression vectors harbouring the Xenopus Smad1
wild type, the C domain, the (C+P) domain, the N domain, the (N+P) domain, or the P domain
was permanently transfected into the murine mesenchymal progenitor cell C3H10T1/2 and
BMP2 expressing C3H10T1/2 cells.
The differentiation potential of C3H10T1/2 and C3H10T1/2BMP2 cells expressing recombinant
Smad1 or its domains was investigated by histological staining and also by RT-PCR analyses
of the expression of several marker genes, which are specific or typical for osteogenic-,
chondrogenic-, and adipogenic development. The following results were obtained: 
• Smad1 and its biological active C domain initiated osteogenic development in the
C3H10T1/2 cells and stimulated in C3H10T1/2BMP2 cells differentiation into osteogenic
lineages.
• The N domain was sufficient to initiate transcription of osteogenic maker genes such as the
osteocalcin or PTH/PTHrP receptor gene in parental C3H10T1/2 cells. In general, however,
this domain blocked osteogenic development when recombinantly expressed in
C3H10T1/2BMP2 cells. 
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• The P domain dominant-negatively inhibited the BMP2-dependent osteogenesis in
C3H10T1/2 cells. C3H10T1/2-Smad1 C cells expressing different amount of expression vector
harbouring Smad1 P domain showed that the P domain of Smad1 inhibited osteogenesis in a
dose dependent manner. 
• C3H10T1/2BMP2 cells expressing recombinant Smad3 P domain revealed that the inhibitory
effect of P domain on osteogenesis is not a common property of all Smads,  but seems specific
for Smad1. 
• Smad1 and its domains do obviously not participate in the BMP2-dependent chondrogenic
development, since they could neither differentiate C3H10T1/2 cells into chondrocytes nor
was the chondrogenic potential of C3H10T1/2BMP2 cells influenced by Smad1 or its domains. 
•  Adipogenic development was affected by Smad1 or its domains in C3H10T1/2 cells, but
other factors, appears to complement Smad1 in this process.
• The trancriptional assays of promoter luciferase constructs for some BMP-responsive genes,
such as PTH/PTHrP receptor, JunB, and Msx1, substantiated the histological and genetic
analyses of Smad1 function by showing stimulation of the promoter luciferase activities by the
Smad1 C domain. 
•  The interference of the Smad1 P domain with Smad1 C domain-dependent stimulation of
luciferase activity suggests that the Smad1 P domain might form a complex with the Smad1 C
domain and thereby inhibits the translocation of Smad1 C domain into the nucleus.
The analysis of effects of the Smad1 domains has important value in understaning the process
of BMP2-dependent osteo-/chondrogenic development in mesenchymal progenitors
(C3H10T1/2).
4 Summary
98
5 Methods
5.1 General methods  
5.1.1 Frequently used buffers and solutions
TE(10/0,1) 10 mM Tris-HCl (pH7.5)
0.1 mM EDTA
25 x TA 1 M Tris-HCl (pH8.0)
50 mM EDTA
PBS: 140 mM NaCl (pH 6.8- 7.0)
(Phosphate Buffered Saline) 27 mM  KCl
7.2 mM Na2HPO4 x 2 H2O
14.7 mM KH2PO4 
5.1.2 Sterilization
Glassware was sterilized for 2 hours at 180°C. Plasticware and most of the solutions were
autoclaved. The solutions which can not be autoclaved were sterilized by filteration.
5.2 General methods of DNA cloning (Maniatis, 1989)
5.2.1 DNA digestion with restriction endonucleases
Digestion of DNA with restriction endonucleases was carried out by incubating the
enzyme(s) with DNA using appropriate reaction conditions. The amounts of enzyme and
DNA, buffer and ionic concentrations, and the temperature and duration of the reaction
varied depending upon the specific application. Most of the restriction enzymes are active
at 37°C. Under optimal conditions one unit (1 U) enzyme cleaves 1 µg DNA within one
hour. The reaction was stopped by incubating for 15 min at 65°C. Heat resistant enzymes
were inactivated by extraction with phenol, DNA was precipated from the aqueous phase
by ethanol. 
Buffer for BamHI: NEBuffer BamHI
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       150 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT
       (pH 7.9). Supplement with 100 µg/ml BSA.
Buffer for Bgl II:    NEBuffer 3
       100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT
        (pH 7.9). 
Buffer for EcoRI:   NEBuffer EcoRI
       50 mM NaCl, 100 mM Tris-HCl, 10 mM MgCl2, 0.025% Triton 
       X-100 (pH7.5).
Buffer for Hind III: NEBuffer 2
        50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT 
        (pH7.9)
5.2.2 Agarose gel electrophoresis of DNA
Agarose gels of appropriate concentration (from 0.5% to 2.0%) were used to separate
DNA fragments of different sizes. Agarose was melted in 100 ml 1x TA-running buffer
(400 mM Tris-acetate; 20mM EDTA, pH 8) in a microwave oven and was swirled to
ensure even mixing. The final concentration of ethidium bromide incorporated in gel and
electrophoresis buffer was 0.5 µg/ml. The melted agarose should be cooled to 55°C before
pouring into the gel chamber with gel comb. After the gel was hardened, the gel chamber
was placed in the electrophoresis tank which was filled with 1x TA running buffer until the
buffer covered the gel to a depth of 1 mm. The samples together with an appropriate
standard for size determination were mixed 10x loading buffer (20% Ficoll; 0.1% Orange
G; in TE) and added to the sample wells. The ideal running condition is 5 Volt per cm. 
0.1 - 3 kb2.0%
0.2 - 4 kb1.5%
0.2 - 6 kb1.2%
0.4 - 8 kb1.0 %
0.8 - 15 kb0.5 %
Effective range of resolution for linear DNA fragmentsAgarose gel
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5.2.3 DNA and RNA standards
DNA standards:
Lambda DNA /EcoRI+ HindIII Marker:
21226, 5148, 4973, 4268, 3530, 2027, 1904, 1584, 1375, 947, 831, 564 bp
pBR322 DNA/MvaI( BstNI) Marker:
1857, 1058, 929, 383, 121 bp
100bp DNA Ladder:
1000, 900, 800, 700, 600, 500, 400, 300, 200, 100, 80 bp
pM2 DNA/HaeIII Marker:
1180, 1760, 1410, 860, 845, 672, 615, 525, 333, 295, 272, 167, 152, 120, 
95, 49, 44 bp
RNA standard:
CA3103(BRL): 
9.5, 7.5, 4.4, 2.4, 1.4, 0.24 KB
5.2.4 Isolation of DNA fragments from low melting point agarose gel  
(The chemicals are supplied by "JET-SORB" kit; GENOMED)
This method can be used to purify and isolate DNA fragments after separation by an LMP
(Low Melting Point)-agarose gel. The target band was cut with a scalpel from the 1% LMP
gel and weighed. 300 µl Buffer A1 and 10 µl JETSORB Solution were added to per 100
mg gel. The mixture was incubated at 50°C for 15 min to allow the gel to melt and DNA to
bind to the resin in the JETSORB Solution. After 30 sec at 15 000 x g centrifugation, the
supernatant was discarded and the resin was resuspended in Buffer A1. In the same way the
resin was washed two times with Buffer A2. The resin was air-dried, the DNA was eluted
with an appropriate volume of TE at 50°C for 5 min, centrifuged as before, and the
supernatant containing DNA was saved.
Buffer A1: conc. NaClO4; TBE; NaAc
Buffer A2: EtOH; NaCl; EDTA; Tris/HCl 
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5.2.5 Isolation of DNA fragments from standard agarose gels
(The chemicals are supplied by High Pure PCR Product Purification Kit; Boehringer
Mannheim)
The DNA fragments can also be purified and isolated from standard agarose gels. The
target band was cut from the gel and put into an eppendorf tube, and the weight was
determined. 300 µl Binding Buffer (3 M guanidinium-thiocyanate, 10 mM Tris-HCl, pH
6.6, 5% ethanol) was added per 100 mg gel, incubated at 56°C for 15 min. To ensure that
the gel is totally melten in the Binding Buffer the mixture was vortexed every 2-3 min. 150
µl isopropanol was added per 100 mg gel, followed by 10 sec vortexing. A filter tube was
put onto an accepting tube and the DNA solution was pipetted into the filter tube. After 30
sec centrifuging at 13 000 g, the filter tube was washed with 500 µl Washing Buffer (20
mM NaCl, 10 mM Tris-HCl, pH 7.5) and 200 µl Washing Buffer, respectively, as before.
For elution of bound DNA, the filter tube was put onto a clean eppendorf tube, 50-100 µl
TE was added. After centrigfuging, the DNA solution was available for further analysis.
5.2.6 Purifying and concentrating of DNA from aqueous solutions
Phenol extraction or ethanol precipitation were offen used to remove proteins and solute
molecules from aqueous solutions, or to concentrate DNA solutions. An equal volume of
phenol/choroform/isoamyl alcohol (25:24:1) was added to the DNA solution. The mixture
was vortexed vigorously for 10 sec and microcentrifuged 45 sec at RT. The top (aqueous)
phase containing DNA was carefully transferred to a new tube. 1/10 volume of 3 M sodium
acetate (pH 5.2) was added to the DNA solution, mixed briefly. 2 to 2.5 volumes of
ice-cold 100% ethanol was added to the mixture from which DNA was precipated at -70°C
 for 15 min to 1 hr.
The sample was centrifuged for 15 min at high speed. 1 ml 70% ethanol was added to the
pellet. The tube was inverted several times, followed by centrifugation. The pellet was
air-dried and was dissolved in an appropriate volume of TE buffer (pH 8.0) and stored at
-20°C.
5.2.7 Removal of low-molecular-weight oligonucleotides and triphosphates  
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Using ammonium acetate in place of sodium acetate allows the preferential precipitation of
longer DNA molecules. Therefore, the small single- or double-stranded oligonucleotides
can be removed from DNA solutions.
An equal volume of 4 M ammonium acetate (pH 4.8) was added to the DNA solution, and
mixed well. Then 2 volumes of ice-cold 100% ethanol were added, vortexed 10 sec and
processed as described in 5.2.6.
5.2.8 Quantification of nucleic acids
5.2.8.1 Measurement of absorbance
The concentration-dependent absorbance of nucleotides at 260 nm can be used to
determine the concentration of DNA or RNA solutions. The nucleic acid solution was
diluted 1:50 or 1:100 with water. 100 µl (water as a reference) was added into a quartz
cuvette, absorbance was measured at 260 and 280 nm. 1 OD 260 equals 50 µg/ml
double-stranded DNA or 40 µg/ml single-stranded DNA or RNA. A carefully prepared
nucleic acid solution has a ratio of OD260/OD280 between 1.5 and 2.0.
5.2.8.2 Qualification in agarose gels
Alternatively to the method described above, the concentration of nucleic acids can be
determined by staining the agarose gel with ethidium bromide. A defined amount of marker
was used as a standard to run a gel in parallel with the DNA in question. The gel was
documented with a digital camera and analysed with appropriate software (WINCAM from
CYBERTECH). 
5.2.9 Dephosphorylation of DNA
Alkaline phosphatase (Shrimp Alkaline Phosphatase, USB) was used to dephosphorylate
the 5´-termini of DNA-ends in order to prevent vector self-ligation.
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5 µg DNA were mixed with 5 U alkaline phosphatase in 1x alkaline phosphatase buffer and
incubated at 37°C for 1 hr. The reaction was stopped by heating to 65°C  for 10 min or
extracting with phenol.
10 x alkaline phosphatase buffer:
200 mM Tris-HCl, pH 8.0
100 mM MgCl2
5.2.10 Ligation of DNA fragments
The Ready-To-Go T4 DNA Ligase Kit (Pharmacia) was used to ligate DNA fragments. T4
DNA ligase catalyzes the repair of single-stranded nicks in duplex DNA and joins duplex
DNA restriction fragments having either blunt or cohesive ends. It is the only ligase that
efficiently joins blunt-end termini under normal reaction conditions. 
The vector was digested with restriction enzymes and dephosphorylated as described
before, and the DNA insert was also digested with appropriate restriction enzymes to get
compatible ends. For sticky-end ligation, the ratio of vector to insert DNA was 1:1 to 1:2
(total DNA is 200 ng to 500 ng). The dry ligation mixture was dissolved with 20 µl DNA
solution of vector and insert. The ligation sample was incubated at 16°C overnight. For
blunt-end ligations, the ratio of vector to insert DNA was 1:1 to 1:4 (total DNA is 200 ng
to 1000 ng). Blunt-end ligations were performed at RT.
After ligation, the mixture was precipitated with 0.5 vol. NaCl and 0.6 vol. Isopropanol for
1 hr at -70°C, afterwards centrifuged at 4°C and 20 000x g. The pellet was washed 2 times
with 70% ethanol and dissolved in TE.
The dry ligation mixture:
6 U Weiss T4 DNA ligase
66 mM Tris-HCl, pH 7.6
6.6 mM MgCl2
0.1mM ATP, 0.1 mM Spermidine, 10 mM DTT.
5.3 Work with E.coli
5.3.1 E.coli line
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E.coli SURE (Stop Unwanted Rearrangement Events), (Greener, 1990):
recB, recJ, sbcC201, uvrc, umuC: Tn5 (kanR), mcrA, mcrB, mrr lac, T (hsdRMS), endA1,
gyrA96, thi, relA1, supE44{F’, proAB, lacIqZ U  M15 FN10 (tetR)}
5.3.2 Culture media:
LB-Medium: 
Bacto-Trypton  10 g/l
 Bacto-yeast extract  5 g/l
NaCl 5 g/l
TB-Medium: 
Bacto-Trypton 12 g/l
Bacto-yeast extract 24 g/l
87 % Glycerol  4 ml
KH2PO4 17 mM 
K2HPO4 72 mM
SOB-Medium:
Bacto-Tryptone  2 %
Bacto-yeast extract 0,5 % 
NaCl 10 mM 
KCl 2.5 mM
MgCl2 10 mM
MgSO4 10 mM
SOC-Medium: 
SOB-Medium with 20 mM Glucose
Agar Plates: 
7.5g/l Bacto-Agar in LB-medium
Ampicilline:
working concentration: 50 mg/l; stock solution: 25 mg/ml in 70 % Ethanol
Tetracyline: 
working concentration: 5 mg/l; stock solution: 5 mg/ml in 100 % Ethanol
Kanamycin: 
working concentration: 50 mg/l; stock solution: 50 mg/ml in water
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5.3.3 Conservation of bacterial strains (Maniatis et al, 1989)
A bacterial strain can be stored on a culture plate for 2-4 weeks at 4°C.  For permanent
storage, 1 ml overnight culture of the desired strain was mixed with 1 ml autoclaved
glycerol (87 %) and was kept at -70°C.
5.3.4 Preparation of competent cells (Dower et al, 1988)
A single clone of E.coli SURE was incubated in 2 ml LB medium with tetracyline overnight
at 37°C with moderate shaking. This preculture was transferred into 1000 ml LB medium in
a sterile 2-liter flask (which allows for sufficient aeration) and cultured at 37°C  with
moderate shaking for 2 to 5 hr until an OD600 of  0.6 to 0.7  was reached. 
The cells were aliquoted into four 250-ml flasks and incubated on ice for 30 min. The cells
were centrifuged 15 min at 1500 x g, 4°C. Each pellet was resuspended thoroughly but
gently in 250 ml ice-cold sterile deionized water. The cells were centrifuged again, and
washed with 100 ml ice-cold steriled water. After centrifugation the pellets were pooled
with 10 ml ice-cold sterile glycerol (10%; w/v) and centrifuged again. The pellet was
resuspended with 2 ml glycerol. All steps should be performed on ice. The cells were
dispensed into pre-chilled 1.5 ml eppendorf tubes, and were frozen immediately in liquid
nitrogen. The competent cells were stored at -70°C.      
                                  
5.3.5 Transformation by high voltage electroporation
Electroporation with high voltage is currently the most efficient method for transforming E.
coli with plasmid DNA. Competent cells were thawed on ice. 1 µl of the DNA solution to
be transformed was added to 50 µl competent cells, mixed well, and incubated for 1 min on
ice. The transformation mixture was transferred into an electroporation cuvette (gap width:
0.2mm) and pulsed at 2.5 kV/25 µF/200 Ohm. 1 ml pre-warmed SOC medium was added
immediately afterwards. The cells were transferred into a sterile culture tube, and incubated
1 hr with moderate shaking at 37°C. The transformation culture was spread on LB plates
containing appropriate antibiotics and incubated at 37°C overnight.
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5.3.6 Identification of recombinant bacterial clones by PCR 
PCR (Polymerase Chain Reaction) can be used to check for positive clones if there are
specific primers available. Single clones were picked with a tooth-pick and transferred into
20 µl TE as well as onto a master-plate. The master plate was incubated at 37°C. PCR was
performed with 50% of the DNA solution as template. PCR products were checked by gel
electrophoresis.
5.3.7 Isolation of plasmid DNA from E. coli (Birnboim and Doly 1979)
5.3.7.1 Minipreps of plasmid DNA
This is the most commonly used protocol for isolation of small quantities of plasmid DNA
from bacterial cells. Bacterial cells were lysed by treatment with a solution containing SDS
and NaOH (SDS denatures bacterial proteins, and NaOH denatures chromosomal and
plasmid DNA). The mixture was neutralized with potassium acetate, causing the covalently
closed plasmid DNA to reanneal rapidly whereas most of the chromosomal DNA and
bacterial proteins remained precipitated and could be removed by centrifugation. The
reannealed plasmid DNA from the supernatant was then concentrated by ethanol
precipitation.
Single clones were picked for simultaneous inoculation of a master-plate and a 2
ml-culture, both of which were incubated overnight at 37°C. The next day the overnight
cultures were transferred into a 2 ml eppendorf tube and centrifuged by 8000 rpm for 1
min. The cell pellet was resuspended in 200 µl GTE solution (Glucose 50 mM, Tris-HCl  
25 mM, pH 8.0, EDTA 10 mM, 4 mg/ml Lysozym, optional) and incubated for 5 min at
RT. 400 µl of freshly prepared denaturing-solution (NaOH  0.2 N, SDS (w/v) 1 %) was
added and  incubated  for 5 min on ice. 300 µl 7.5 M ammonium acetate was added and
incubated again on ice for 10 min. Cell debris and chromosomal DNA were pelleted at 13
000 x g for 10 min. The supernatant was transferred to a new tube, mixed with 0.6 vol.
isopropanol, and placed for 15 min at -70°C to precipate nucleic acids. A 10 min
centrifuging at 13 000 x g pelleted plasmid DNA. The pellet was washed with 1 ml of 70 %
ethanol, air-dried, and dissolved in 100 µl TE.
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To confirm whether the clone contained the desired insert, 10 µl of the DNA was used for
a restriction digest with appropriate enzymes.
5.3.7.2 Maxi prep of plasmid DNA  
(The chemicals are supplied by JETSTAR kit, GENOMED Inc.)
JETSTAR is a new and unique anion exchange resin developed by GENOMED. The kit
was designed to combine binding of DNA to columns with a modified alkaline/SDS lysis
procedure for the preparation of plasmid DNA. The JETSTAR-purified plasmid DNA is
reported to be of a higher quality than 2 x CsCl-purified plasmid DNA.
Bacterial colonies harboring the desired recombinant plasmid were cultivated in 2-3 ml LB
with appropriate antibiotics at 37°C with vigorous shaking for 7-9 hr. 1-2 ml of the
preculture was transferred into 250-500 ml LB medium with antibiotics (in a 2-Liter flask)
and incubated at 37°C  with vigorous shaking overnight.
The cells were collected by 10 min centrifuging at 4°C, 6000 x g. The pellet was
resuspended in 10 ml Cell Resuspending Solution (50 mM Tris-HCl, pH 8.0, 10 mM
EDTA) until homogeneous. 10 ml Cell Lysis Solution (200 mM NaOH, 1 % SDS (w/v))
was added to the suspension and mixed gently. The mixture was incubated for 5 min at RT.
Then 10 ml Neutralization Solution (3.2 M potassium acetate/ acetic acid, pH 5.0) was
added and mixed immediately but gently. The mixture was centrifuged for 15 min at 20°C,
15 000 x g. The supernatant was applied onto the column, which had been equilibrated by
Column Equilibration Solution (600 mM NaCl, 100 mM sodium acetate/acetic acid, pH
5.0, 0.15 % Triton X-100). The column was washed with 60 ml Column Washing Solution
(800 mM NaCl, 100 mM sodium acetate/ acetic acid, pH 5.0). Then pre-warmed (50°C)
DNA Elution Buffer (1250 mM NaCl, 100 mM Tris-HCl, pH 8.5) was added to the
column, the eluate was collected in a 30 ml Corex tube. 0.7 vol. isopropanol was added to
precipitate DNA and kept at -70°C for 15 min. The DNA solution was centrifuged for 30
min at 4°C, 15 000 x g. The pellet was washed 2 times with 5 ml 70 % ethanol each and
recentrifuged. The pellet was air-dried and dissolved in 1ml TE.
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5.4 Cloning of cDNAs (Frohman et al. 1990)
5.4.1  Reverse transcription of mRNA 
(SuperScriptTMRNase H- Reverse Transcriptase kit, GIBCO-BRL, 18053-017)
SuperScript TM RT RNase H Reverse Transcriptase is produced from a cloned M-MLV RT
gene from which the RNase H sequence has been deleted, reducing the RNase H activity to
nondetectable levels. The enzyme can be used to synthesize first strand cDNA and will
generally result in higher yields of cDNA and more full length products.
5 µg total RNA or 0.5 µg mRNA and 1 µl Oligo (dT)
 12-18 (500 µg/ml)a, which binds to the
3´-poly(A)-end of mRNA, were mixed in a 1.5 ml nuclease-free eppendorf tube, water was
added to a final volume of 12.6 µl. The mixture was heated to 70°C for 10 min and quickly
chilled on ice. The contents of the tube were collected by brief centrifugation. Then 7.4 µl
reaction solution was added to the tube and mixed by gently vortexing. The tube was
equilibrated at 37°C for 2 min. 1 µl (200 U) of SuperScript RT was added to the mixture,
mixed gently, and incubated at 37°C for 30-60 min. 30 µl TE was added to the mixture and
the reaction was terminated by heating to 90 °C for 5 min followed by quickly chilling on
ice.     
 reaction solution:
5 x First Strand Buffer 4 µl 
0.1 M DTT 2 µl
dNTP stock (10mM) 1 µl
RNasinR RNase Inhibitor 0.4 µl ( 16 U)
5 x first strand buffer:
Tris-HCl, pH 8.3 250 mM
Kcl 375 mM
MgCl2 15 mM
            
5.4.2 PCR (Polymerase-Chain-Reaction)-Amplification
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Reverse transcription of RNA followed by the Polymerase Chain Reaction (RT-PCR) is an
extremely sensitive method to amplify specific DNA fragments of interest from a mixture,
or to detect and quantity specific mRNAs, respectively.
Traditionally, levels of individual mRNAs have been analyzed by procedures such as
Northern blots, RNA dot/slot blots, nuclease protection and in situ hybridization.
Application of the polymerase chain reaction technique provides another method of mRNA
analysis. This PCR-based method has been variously termed RNA-PCR (Kawasaki et al.,
1991), RT-PCR (Rappolee et al.,1991), RNAphenotyping (Chelly et al., 1988), and
Message Amplification Phenotyping (MAPPing) (Brenner et al., 1989). The RT-PCR
method has become increasingly popular for analysis of gene transcripts, primarily because
it is highly sensitive and rapid.
Basic PCR components include reaction buffer, dNTPs, primers, cDNA template and a
thermostable DNA polymerase. Taq Polymerase works at different Mg2+ concentrations
and different temperatures (the optimum temperature is 72°C). Moreover heat resistance
even at 94°C allows to change the temperature, in order to place the molecule under the
best conditions of amplification possible. The primers used should exactly match the cDNA
template and flank the 5’ and 3’ ends of the template DNA. The samples are analyzed by
agarose gel electrophoresis.
Standard conditions for PCR amplification: (total volume: 20µl)  
Template DNA 0.1 ng/µl
Nucleotide 250 µM
Taq-Polymerase 0.025 U/µl
MgCl2 2.5 mM
10 x PCR Buffer 2µl
Primer (5’+ 3’) 0.1 pmol/µl
The standard PCR program:
Precycle:
94°C 1 min
Followed by about 30 cycles:
94°C 20 sec       Denaturing of DNA
X °C 20 sec      Primer annealing (the temperature is primer-pair specific)
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72°C 30 sec       Elongation of DNA
Final cycle:
72°C 3 min       Completion of DNA-fragments 
10 x PCR Buffer:
KCl 500 mM
Tris-HCl, pH 8.3 100 mM
gelatin 0.01%
dNTP- Mixture:
dATP 10 mM
dGTP 10 mM
dCTP 10 mM
dTTP 10 mM
5.4.3 Cloning of PCR Products
(All chemicals are from ExpandTMHigh Fidelity PCR System, Boehringer Mannheim)
In this protocol, synthetic oligonucleotides incorporating restriction sites are used to
amplify a region of DNA to be subcloned into a vector containing compatible restriction
sites. The ExpandTM High Fidelity PCR System, is composed of a unique enzyme mix
containing thermostable Taq DNA and Pwo DNA polymerases (Bernes et al., 1994). This
powerful polymerase mix is designed to give PCR products with high yield, high fidelity
and high specificity from episomal and genomic DNA. Due to the inherent 3’-5’
exonuclease proofreading activity of Pwo DNA polymerase this system results in increased
accuracy of DNA synthesis (0.85 x 10-5 error rate) compared to Taq polymerase (2.6 x 10-5
error rate).
Two master mixes are set up as follows (all on ice):
Master mix 1 (25 µl):
dNTPs 1 µl final concentration 200µM
Primer (3’+5’) 3 µl final concentration 300nM
Template DNA 10-100 ng
sterile redist. H2O up to 25 µl
Master mix 2 (25µl):
10 x Expand HF buffer with 1.5 mM MgCl2 5 µl
ExpandTM High Fidelity PCR System enzyme0.75 µl (2.6 U)
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sterile redist. H2O up to 25 µl
Master mixes 1 and 2 were pipetted together on ice and PCR was performed as described
before.
The amplified DNA fragment was purified by phenol extraction, and was recovered from an
LMP gel.  Following the procedure outlined in 5.3.10. the DNA fragment was ligated into
the digested vector (if necessary, the vector should be dephosphorylated after restriction
digestion). 
5.4.4  DNA Sequencing
5.4.4.1. Sequencing of DNA with „ALF“ Pharmacia
Cycle-Sequencing is based on the Didesoxy-method (Sanger et al., 1977). This method
utilizes a thermostable DNA-Polymerase to synthesize a complementary copy of a
single-stranded DNA template. The method makes use of the ability of the DNA
polymerase and also use 2’, 3’-dideoxynucleoside triphosphates (ddNTPs) as substrates.
When a specific ddNTP is incorporated at the 3’ end of the growing DNA chain, elongation
is terminated because the chain lacks a further 3’-hydroxyl group. In each of the reactions,
only one of the four possible ddNTPs is included. The ddNTP:dNTP ration in each reaction
is adjusted so that chain termination occurs at each respective position of ddNTP. In this
way, each of the four elongation reactions contains a population of extended chains, which
have a fixed 5’ end as specified by the annealed primer and a variable 3’ end terminating at
a specific dideoxynucleotide. The fragments can be separated by a denaturing
high-resolution polyacrylamide gel according to their length. Single fragments are detected
and identified by the fluorescence labeled primer.
5.4.4.1.1 Preparation of sequencing gel
The accuracy of DNA sequence determination depends largely upon resolution of the
sequencing products in denaturing polyacrylamide gels. A thorough washing and rinsing of
the gel plates were necessary. The part near the sample-wells was silanized with silanizing
solution, wiped with ethanol and dried. The gel plates were assembled according to the
manufacturer’s instructions with 0.2 or 0.4 mm uniform-thickness spacers and clamps,
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making sure that the side and bottom spacers fit tightly and closely together. The gel
solution was filtered, then 70 µl TEMED and 300 µl 10 % APS were added. The gel
solution was poured evenly to avoid air bubbles. Then the shark tooth comb was inserted.
The gel was polymerized for at least 1.5 hr. After polymerization, the bottom spacer and
the shark tooth comb were gently removed. The upper reservior was fixed and the gel was
placed in the ALF-Sequencer. The reserviors were filled with 1 x TBE buffer.
silanizing solution:
ethanol 500 µl
Bind Silane 2 µl
CH3COOH, 10 % 125 µl 
gel solution:
Urea 33.6 g
10 x TBE 9.6 ml
Acrylamide/Bisacrylamide 30 % (29:1) 17.6 ml
deionized H2O  up to 80 ml
5.4.4.1.2 Cycle-Sequencing
For each sequencing reaction: 
10 x Buffer 2.0 µl
 labelled primer (2 pmol) 1.0 µl
dNTPs (1 mM) 4.0 µl
Taquenase/PPase 0.16 µl
(from Amersham Life Science, Inc. Thermosequenase; Product No.: E79000Y)
10x Puffer:
Tris-HCl, pH9.5 120 mM
MgCl2 40 mM
(NH4)2SO4 150 mM
dNTPs:
dATP, dCTP, dTTP, 7deaza-dGTP
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0.5 to 1 µg DNA was added to the reaction mixture, and H2O was used to fill the volume
up to 20 µl. Each 5µl of this solution was transferred into a PCR-tube, and 2 µl
didesoxynucleotide solution was added to each of the four PCR tubes.
Didesoxynucleotide solution:
ddATP 5 µM
ddCTP 5 µM
ddGTP 3.75 µM
ddTTP 5 µM
PCR-reaction:
94°C 120 Sec. 1 cycle
94°C 15 Sec.
X°C 15 Sec. 36 cycles
72°C 40 Sec.
72°C 300 Sec. 1 cycle
4°C Until the stop solution is added.
„X“ equals the optimal annealing temperature of the primer.
When the PCR reaction was finished,  4 µl Stop Solution (formamide 95 %, NaOH 10 mM,
bromophenol blue 0.005 %) was added to each tube. The samples were denatured at 95 °C
for 2-3 min, then chilled on ice until used. The gel was run at 50°C, 1500 Volt, and 35 mA
for 8 hrs. The raw data were analysed by ALF-Software.
5.4.4.2 Sequencing  with ABI Prism 310 Genetic Analyzer
(The chemicals are supplied by PE Applied Biosystems)
PE Applied Biosystems has developed a cycle sequencing kit with AmpliTaq DNA
polymerase, FS. This enzyme is a variant of thermus aquaticus DNA polymerase that
contains a point mutation in the active site resulting in less discrimination against
dideoxynucleotides, which leads to a much more even peak intensity pattern. The second
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mutation is in the amino terminal domain that virtually eliminates the 5’→3’ nuclease
activity of AmpliTaq DNA polymerase. 
5.4.4.2.1 Preparing sequencing reactions
For each reaction, the following reagents were added to a separate 0.2 ml MicroAmp PCR
tube.
Terminator Ready Reaction Mix 4.0 µl
Template 400 ng
Primer 3.2 pmol
Deionized water  up to 20 µl
PCR programm :
96°C 30 sec
X°C 15 sec 25 Cycles
60°C 4 min.
4°C hold
5.4.4.2.2 Purification of the PCR product
For each sequencing reaction, a 1.5 ml microcentrifuge tube was prepared containing the
following: 2.0 µl of 3 M sodium acetate (pH 4.6); 50 µl 100 % ethanol. The PCR reaction
was pipetted into the 1.5 ml tube and mixed thoroughly. The tube was kept on ice for 10
min to precipitate small extension products, then centrifuged 30 min at RT at maximum
speed. The supernatant was carefully discarded. 250 µl 70% ethanol was used to rinse the
pellet, vortexed and recentrifuged for 15 min. The pellet was dried by incubating at 37°C.
12 µl TSR (Thermosuppressor Reagent, from PE Applied Biosystems) was added and
carefully mixed and spinned for 10 sec to keep the contents at the bottom. The mixture was
incubated at 95°C for 2 min, then chilled on ice. After the samples had cooled they were
vortexed again and spinned down. The contents of the tubes were transferred into ABI
sample-vials, avoiding air bubbles. The samples were loaded in the ABI Prism 310 Genetic
Analyzer before capillary electrophoresis.
Terminator Ready Reaction Mix (All chemicals are from PE Aplied Biosystems) :
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A-Dye Terminator labeled with Dichloro 
C-Dye Terminator labeled with Dichloro
G-Dye Terminator labeled with Dichloro 
T-Dye Terminator labeled with Dichloro 
deoxynucleoside triphosphate (dATP, dCTP, dITP, dUTP)
AmpliTaq DNA Polymerase, FS, with the thermally stable pyrophosphatase
MgCl2
Tris-HCl, pH 9.0
5.5 Work with eukaryotic cells
5.5.1 Cell lines
C3H10T1/2:  Fibroblast cells from mouse embryo (Reznikoff et al. 1973)
ATCC Nr.: CCL 226
C243/3TP-Luc: C243 cells expressing 3TP-Luc promoter construct 
NIH 3T3:
5.5.2 Culture media and solutions
DMEM (dulbecco’s modified eagle’s medium):
13.63 g/l DMEM powder
44 mM NaHCO3
10 mM HEPES
1 x PEN/STREP, 1 x Glutamine, and 10 % FCS are added before use
100 x PEN/STREP:
6.06 mg/ml penicillin
10 mg/ml streptomycin
100 x glutamine:
200 mM L-glutamine
FCS (fetal calf serum):
Heat-inactivated 30 min at 56°C. Aliquot and store at -20°C.
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Heat-inactivated serum is required for long-term cultures. The heat 
treatment serves to reduce the number of viral and other adventitious 
contaminants and is required to inactivate complement.
PBS (phosphate buffered saline):
NaCl 150 mM
KCl 27 mM
Na2HPO4 7.2 mM
KH2PO4 14.7
TEP:
Trypsin 3 ml 2.5%
EDTA 125 µl 0.5 M , pH 7.5
PBS 100 ml
100 x Ascorbate/ß-glycerophosphate:
ß-glycerophosphate 9.7 g 1 M
ascorbic acid 225 mg 5mg/ml
DMEM 45 ml
differentiation medium: 
DMEM
FCS 10 %, 1 x PEN/STREP, 1 x Glutamine, 1 x 
ascorbic acid/ß-glycerophosphate
G418:
100 mg/ml stock solution
750 µg/ml working solution
Puromycin:
2.5 mg/ml stock solution
5 µg/ml working solution
 
5.5.3 Culture conditions 
The adherently growing C3H10T1/2 cells were cultivated in culture flasks, dishes or
6-well-plates, 12-well-plates  with DME-medium containing supplements with 5 % CO2
concentration in a 37°C incubator. After reaching confluence (arbitrarily termed day 0)
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differentiation medium were added as specified in the protocol of Owen et al (1990) for the
cultivation of native osteoblast-like cells.
5.5.4 Conservation of eukaryotic cells
5.5.4.1 Thawing of cells
The cells in liquid nitrogen should be rapidly unfrozen in a 37°C water bath with swirling.
Then the cells were transferred into a Roux-flask (75 cm2) containing 12 ml warm medium.
The medium was changed 2 hr later in order to remove DMSO contained in the freezing
medium.
5.5.4.2 Subcultivation 
The cells were subcultivated when they reached 80-90 % confluence. The medium was
carefully removed and the cells were washed with warm PBS. Pre-warmed TEP (for a
small Roux-flask 1 ml, for a middle one 2 ml) was added to the flask. After 2 or 3 min the
cells became dislodged from the bottom of the flask. Pre-warmed culture medium was
added to inactivate the trypsin. The cells were gently mixed and dispersed. Their number
was determined with the help of a fuchs-rosenthal-counting chamber, so that the desired
number of the cells could be seeded in a new flask or dish.
5.5.4.3 Freezing of cells
The cells in a medium Roux-flask were trypsinized ( 5.5.4.2), mixed with 8 ml medium,
transferred to a sterile 10 ml tube, centrifuged at RT by 1500 rpm for 5 min. The
supernatant was carefully sucked off, the cell pellet was resuspended in 4 ml
freezing-medium (DMSO 5 %, FCS 95%). The cell suspension was aliquoted  into 4 vials
and kept at -70°C overnight. The next day the cells were transferred to liquid nitrogen for
long-term-storage.
5.5.5 Fixation of cells 
5.5.5.1 methanol
After removal of culture medium, cells were washed once with PBS. The cells were
covered with methanol and stored for 15 min at -20°C. Then methanol was thoroughly
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socked off and the cells were washed 2 times with PBS. The cells were stored in sterile
water or PBS at 4°C .
5.5.5.2  3 % paraformaldehyde
Cells were washed once with PBS. 3 % paraformaldehyde was then added and incubated
for 30 min at RT. After washing 2 times the cells were stored in PBS or sterile water at 4°C
for several weeks.
paraformaldehyde 3 % (w/v) in PBS (heat to 80°C to dissolve, filter at RT)
5.5.6 Transduction of DNA into Mammalian Cells
( Dosper Liposomal Transfection Reagent, Boehringer Mannheim, Cat. No. 1811169)
There are two types of transfections that are routinely performed with mammalian cells:
transient and permanent ones. In a transient transfection, transcription or replication of the
transfected gene can be analyzed between 1 and 4 days after introduction of the DNA.
However, many experiments require formation of cell lines that contain genes that are
stably integrated into chromosomal DNA resulting in a permanent transfection.
Widely used techniques include the calcium phosphate coprecipitation method (Wigler et
al. 1977), electroporation (Potter et al. 1988), viral vectors (Perkus et al. 1993), and
cationic liposome-mediated transfection (Felgner et al. 1987). 
Dosper Liposomal Transfection reagent is a liposome preparation of the polycationic lipid
1,3-di-oleoyloxy-2-(6-carboxy-spermyl)-propylamide, consisting of a spermine head group
and fatty acid tails. Due to this positively charged spermine head group, Dosper binds
negatively charged DNA molecules. This binding results in the formation of polycationic
complexes that are non-specifically absorbed to the overall negatively charged surface of
the cells to be transfected. Subsequently, the DNA is taken up by the cell.
5.5.6.1 Permanent transfection of DNA into mammalian cells
C3H10T1/2 cells were plated into 12-well-plates at 5000 cell/cm2. The cells were incubated
at 37°C in an incubator until 60-80% confluent. On the day of transfection (usually 24 hr
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after plating), the culture medium was replaced by 2 ml fresh medium without serum 2 hr
before transfection. The transfection mixture was prepared 1.0 hr before transfection.
Solution A: 1.5 µg DNAto be transfected and 0.15 µg selection plasmid were diluted 
with HBS to a final volume of 50 µl
Solution B: 6 µl Dosper was diluted with HBS to a final volume of 50 µl
Solution A and B were mixed gently by air bubbles from pipet-tips, then incubated at RT
for 15 min to allow the Dosper/DNA complex to form. 900 µl of fresh medium without
serum was added to the 100 µl transfection mixture and mixed gently but thoroughly. After
removing the medium from 12-well-plate, this transfection medium was added onto the
cells, 1 ml per well. The cells were incubated for 6 hr at 37°C. After incubation, 1 ml 20 %
FCS medium was added to each well cells, so that the final concentration of serum was 10
%. 24 hr after transfection the medium was replaced by normal culture medium. The
selective medium was given 48 hr after transfection. The cells were split 1:10 into new cell
culture dishes, fed with selective medium every three days. The large and healthy clones
were picked. RT-PCR was carried out to test whether the DNA has stably integrated into
the genome of the transfected cells.
HBS:
HEPES, pH 7.4 20 mM
NaCl 150 mM
sterile-filtered
Selection markers:
Aminoglycoside phosphotransferase (neo, G418, APH)
Selection condition: 500-800µg/ml in complete medium
Basis for selection: G418 blocks protein synthesis in mammalian cells by 
interfering with ribosomal function. Expression of the bacterial APH gene in 
mammalian cells results in detoxification (Southern et al. 1982).
Puromycin-N-acetyl transferase (PAC, puro)
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Selection condition: 5 µg/ml in complete medium
Basis for selection: Puromycin inhibits protein synthesis. The gene encodes an 
enzyme for the inactivation of puromycin by acetylation (de la Luna et al. 1988).
5.5.6.2 Transient transfection of DNA into mammalian cells
The procedure of transient transfection was almost the same as for permanent transfection,
except that solution A lacked selection plasmid and therefore after transfection the cells
were fed with normal culture medium without selection marker. The cells were cultivated
for appropriate time to allow expression of the transfected gene, then the cells were
harvested and assayed.
5.5.7 RNA isolation from eukaryotic cells
(Tri ReagentR LS, Molecular Research Center. INC.)
The TRI REAGENTRLS is a complete reagent for the isolation of total RNA or the
simultaneous isolation of RNA, DNA and proteins from liquid samples of human, animal,
yeast, bacterial and viral origin. It combines phenol and guanidine thiocyanate in a
mono-phase solution to facilitate the immediate and most effective inhibition of RNase
activity.
The medium of the cells was removed, 0.3 ml of TRI REAGENT LS per 10 cm2 of culture
area was added (for small flask 0.75 ml). The cells were lysed by repeatedly pipetting.
Keeping the lysates at RT for 5 min permits the complete dissociation of nucleoprotein
complexes. (Samples can be stored at this step at -70°C for at least one month). The lysates
were transferred into an 1.5 ml eppendorf tube, supplemented with 100 µl BCP
(1-bromo-3-chloropropane) per 0.75 ml of TRI REAGENT LS. The samples were mixed
vigorously. The mixture was kept for 15 min at RT and then centrifuged at 12 000 x g for
15 min at 4°C. Following centrifugation, the mixture was separated into a lower red,
phenol-chloroform phase, white interphase, and the colorless upper aqueous phase. RNA
remains exclusively in the aqueous phase whereas DNA and proteins are in the interphase
and organic phase. The volume of the aqueous phase is about 70% of the volume of  TRI
REAGENT LS used for homogenization. The aqueous phase was transferred to a fresh
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tube carefully without disturbing the interphase. RNA was precipitated by mixing with
0.5ml isopropanol per 0.75ml of TRI REAGENT LS. Samples were kept at -70°C for 30
min. and then centrifuged at 12 000 x g  for 15 min at 4 °C. RNA preciptates formed a
gel-like or white pellet on the bottom of the tube. The supernatant was discarded and the
RNA pellet was washed once with 1 ml 75% ethnol by vortexing and subsequent
centrifugation at 12 000 x g  for 5 min at 4°C. The RNA pellet was air-dried for 3-5 min  
and was dissolved in DEPC water. The concentration of RNA was estimated
spectrophotometrically.  RNA prepared by this method has an OD260/280 ratio between 1.6
and 1.9. 
50 - 100 µg total RNA can be isolated from a small flask. The isolated RNA was free of
protein and DNA contamination and can be used for Northern analysis, dot blot
hybridization, poly A+ selection, in vitro translation, RNase protection assay, molecular
cloning and for RT-PCR without treatment with DNase or additional purification.
5.5.8  Agarose/formaldehyde gel electrophoresis of RNA
1% agarose/formaldehyde gel is suitable for RNA molecules 500 bp to 10 kb in size. 1.0 g
agarose was dissolved in 72 ml sterile water and cooled to 60°C in a water bath, then 10 ml
of 10 x MOPS running buffer and 18 ml of 12.3 M formaldehyde were added before
pouring the gel.
5 µg RNA was dried by vaccum-speed, then 2 µl DEPC H2O, 5 µl formamide, 2 µl
formaldehyde, 1µl 10 x MOPS, 1 µl EtBr (400 ng/ml), 1 µl 10 x loading buffer were added
and mixed by vortexing, microcentrifuged briefly to collect the liquid, and incubated 15 min
at 55°C. The gel was run at 5 V/cm in 1 x MOPS running buffer until the bromphenol blue
dye had migrated one-half to two-thirds the length of the gel.
10 x MOPS:
MOPS 200 mM
EDTA 10 mM
NaAc, pH 7.1 10 mM
10 x Loading Buffer:
bromophenol blue 0.25 % (w/v)
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xylene cyanol 0.25 % (w/v)
glycerol 50 % (w/v)
EDTA, pH 8.0 1 mM
5.5.9 Histological methods 
5.5.9.1 Alkaline phosphatase staining (Osteoblast staining)
(SIGMA FASTTM BCIP/NBT Buffered Substrate Tablet, Cat. No. B-5655)
Osteoblasts exhibit a stellate morphology displaying high levels of alkaline phosphatase
activity which was visualized by cellular staining with SIGMA FAST BCIP/NBT (5-
bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium) tablets. The tablets have been
developed as a precipitating substrate for the detection of alkaline phosphatase activity.
One tablet is dissolved in 10 ml of deionized and distilled water. The solution contains:
BCIP (5-bromo-4-chloro-3-indolyl phosphate) 0.15 mg/ml
NBT (nitro blue tetrazolium) chloride 0.30 mg/ml
Tris buffer 100 mM
MgCl2 5 mM
Alkaline Phosphatase + BCIP→BCI + PO4 , pH 9.5
BCI + NBT → insoluble, blue color
For the fixed cells in 6-well-plate, 800 µl substrate solution was added per well. The
6-well-plate was kept in the dark for 1 hr. Then the solution was socked off, and the cells
were washed twice with PBS. The cells were stored in PBS or H2O at 4°C. 
5.5.9.2 Alcian Blue staining (Chondrocyte staining)
The fixed cells were washed  with PBS, then covered with alcian blue solution (0.5 %
alcian blue in 1 N HCl). After 6 hr to overnight incubation at RT, the alcian blue solution
was socked out. The cells were washed twice with PBS and stored in PBS or H2O at 4°C.
The chondrocytes are identified by displaying blue color, whereas the other cells are
colorless.
5.5.10  Reporter gene assays
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5.5.10.1 Overview of genetic reporter systems
A central question in molecular and cell biology is how cis-acting DNA sequences and
trans-acting factors act in union to control eukaryotic gene expression. These interactions
are mediated by specific binding of a transcription factor or a complex of factors to
enhancer and promoter elements generally found upstream of the transcription start site.
Direct quantitation of changes in gene expression requires the measurement of specific
mRNAs using techniques such as northern blot hybridizations or nuclease protection
assays. But these procedures can be time-consuming and are not always adequate for
analysis of many different gene constructs and require that the analyzed gene be modified in
some manner to distinguish it from the native gene in transfected cells.
An alternative approach to monitor changes in transcription is to link the presumed
cis-acting sequences from the gene of interest to the coding sequence for an unrelated
reporter gene (Alam and Cook, 1990). To test for complete promoters, the DNA fragment
is placed directly upstream of the reporter gene in a vector lacking endogenous promoter
activity. After introduction of the reporter constructs into an appropriate cell type,
measurement of reporter-gene products provides an indirect estimate of the induction in
gene expression directed by the regulatory sequences. The reporter assays thus take place
at the protein level but not from RNA level. The two levels are frequently, but not always,
correlated with one another.
5.5.10.2 ß-galactosidase reporter assay
ß-Gal Reporter Gene Assay Kit (chemiluminescent), Boehringer Manheim
The LacZ gene from E. coli, which encodes the enzyme ß-galactosidase, is among the most
versatile genetic reporters, having a variety of different substrates. The enzyme catalyzes
the hydrolysis of various ß-galactosides. In addition to its use as a reporter for
uncharacterized cis-regulatory sequences, expression of ß-galactosidase under the control
of a consitutive promoter is frequently used as an internal control to normalize the
variability of other reporter assays. ß-galactosidase is particularly useful for normalizing
CAT and firefly luciferase. 
This assay has two basic steps:
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1. Enzyme reaction:
In this step the substrate, Galacton PlusTM (supplied by ß-Gal Reporter Gene Assay Kit),
becomes deglycosylated by the enzymatic activity of the ß-galactosidase contained in the
sample. This incubation step was performed at pH 7.8, where bacterial ß-galactosidase is
highly active. At this neutral pH, the cleaved dioxetane is protonated and will not produce a
light signal. This stable intermediate accumulates during the reaction, and provides a light
signal once the pH will be raised.
2. Light reaction:
The light reaction is initiated by shifting the pH to a value above 12. Due to this shift in pH
the activated intermediate becomes deprotonated and decomposes with the emission of
light (475 nm). The presence of special polymeric enhancer substances improves the
quantum yield of the chemiluminecent reaction. The light signal is measured by a
luminometer.
The ß-galactosidase expression plasmid-transfected cells were washed three times with cold
PBS. After careful removal of PBS, 300 µl of 1 x Cell Lysis Buffer was added per well of a
12-well-plate. The cells were allowed to incubate for 30 min at RT. All soluble cytoplasmic
and nucleoplasmic components, including ß-galactosidase, were extracted by the lysis
buffer. In the case of adherent cells, nuclei (including DNA packeaged in chromatin) will
remain attached to the vessel surface (Lu et al., 1992).
Cell extracts were transferred into a 1.5 ml eppendorf tube, centrifuged for 5 min. at
maximum speed at 4°C to precipate cellular debris. The supernatant was then transferred
into a new tube, cell extracts were used immediatly or should be stored frozen at -70°C.
Depending on the cell line used, substantial amounts of endogenous lysosomal
ß-galactosidase may be present in the lysate and contribute to the non-specific background.
To reduce background, cell lysate was incubated for 60 min at 50°C (Young et al., 1993).
30 µl deionzed, sterile water and 20 µl cell extracts were added per well of a MTP
(microtiter plate, LB 96-WMP, BERTHOLD). After adding 100 µl Substrate Reagent, the
MTP was covered with a cover foil to avoid evaporation, and was incubated 60 min at RT,
while rocking gently. The Initiation Reagent (1 vol. of Enhancer + 5 vol. Initiation solution)
was diluted with redist. water so that the amount of the Initiation Reagent be one fourth of
the final volume. The MTP was placed into the luminometer (Microlumat LB 96, product
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from firm EG & G Berthold), 100 µl Initiation Reagent was automatically injected. After a
delay of 2 sec, start integration of light production for 8 sec.
5.5.10.3 Firefly luciferase reporter assay
Cloning of the luc gene from the firefly Photinus pyralis (de Wet et a. 1987) provided the
first nonisotopic genetic reporter system with widespread utility in mammalian cells. The
bioluminescent reaction catalyzed by luciferase requires luciferin (the substrate), ATP,
Mg2+, and molecular O2. Mixing these reagents with cell lysates containing luciferase results
in a flash of light that decays rapidly. The light signals are detected by the luminometer
(Lumat LB 9501, product from Berthold). The total light emission is proportional to the
luciferase activity of the sample, which in turn provides an indirect estimate of the
transcription of the luciferase reporter gene. Luciferase is sensitive to degradition by
proteases, and therefore has a half-life of  about 3 hrs in transfected mammalian cells
(Thompson et al. 1993). The following reactions are included:
Luciferase + Luciferin + ATP + Mg2+ → Luciferase/Luciferyl-AMP + PPi
Luciferase/Luciferyl-AMP + O2 → Luciferase + Oxyluciferin + AMP + CO2 + hv
The transfected cells were washed twice with cold PBS to remove the calcium containing
medium thoroughly so that the luciferase reaction is not inhibited by traces of calcium. 1 x
cell lysis buffer from the ß-Galactosidase Kit (Boehringer) was used to lyse the cells. The
procedure is as described in 5.4.10.2.
Cell lysates were gently mixed. 20 µl of the cell lysate was added into 350 µl Luciferase
Reaction Buffer in a measuring tube and mixed gently. The measuring tube was inserted
into the luminometer chamber and was immediately measured. The injector of the counter
was pre-rinsed with diluted luciferin. 50 µl diluted luciferin solution was injected per
sample in the luminometer and light output was measured for 10 sec at 25°C.
Reaction Buffer:
glycylglycine, pH 7.8 25 mM
MgSO4 15 mM
ATP 5 mM 
pH is adjusted with KOH to 7.8
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Normally the reaction buffer is made up as 1.25 x stock solution without 
ATP. Before use, mix 10 ml 1.25 x stock solution with 2.5 ml 25 mM ATP.
luciferin solution:
luciferin 0.4 mM
glycylglycine, pH 7.8 25 mM
luciferin stock solution: 10 mM
luciferin 10 mg in 3.57 ml glycylglycine. The stock solution was divided 
into 40 µl aliqots and stored in the dark at -20°C. When needed, 1 ml 
glycylglycine (pH 7.8) was added into the tube.
5.5.10.4 Statistic evaluation
The luciferase activities were normalized on the basis of ß-galactosidase expression from
pSV ß-galactosidase in all luciferase reporter experiments. All the experiments were
repeated at least three times with similar results. The mean and standard error were
calculated by the following formula:
     
 mean
Sx   standard error
n the number of samples
Xi counts of a sample
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7 Appendix  
7.1 Oligonucleotide
MUR342 bp54 V CAGCATCTGTAGGGGTCTT
CT
RT-Collagen II 3’
MUR342 bp54 W CCCTGTCTGCTTCTTGTAAA
AC
RT-Collagen II 5’
MUR252 bp50 X CCGTAAGTTGGAATGGTTTT
T
RT-CollagenI 3’
MUR252 bp50 Y CGCCCTGCCTGCTTCGTGRT-CollagenI 5’
MUR 3’186 bp57C ZACACGGTGTCACTGCGCT
GAAGA
RT-CBFA1 3’ 
MUR 5’186 bp57 [ CCAGGAAGACTGCAAGAAG
GCTCTGG
RT-CBFA1 5’
MUR127 bp54.8 \ CCACTGCGCTGAAGAGGCT
GTTT
OSF2/CBFA1 2 3’
MUR127 bp54,8 ] CTCACTACCAGCCACCGAG
ACCAA
OSF2/CBFA1 2 5’
bone morphogenetic
protein 2; Wiles, 1995
720 bp50 ^ CAGACGTCCTCAGCGAATTT
G
RT-BMP-2 3’
bone morphogenetic
protein 2; Wiles, 1995
720 bp50 _ CGTTTGTGTTTGGCTTGACG
C
RT-BMP-2 5’
MUR 3’541 bp54,7 ` CATTGTGAAGCCCCCATACC
A
RT-AdipoQ 3’
MUR 5’541 bp54,7 a CGCAACATTCCGGGACTCTA
CTACT
RT-AdipoQ 5’
cloning 5’ primer of
Smad3 P domain
276 bp50 b CATCGAAGCTTTTAACCGTA
GGTGACTGGCTGTAG
P-Smad3 3’
cloning 5’ primer of
Smad3 P domain 
276 bp50 c CTCGAATTCGCCACCATGAT
CCCGGCCGAGTTCCCCCC
ACT
P-Smad3 5’
 pMT7T3 3’ primer45 d CAGCTCAATTAACCCTCACT
AAAGGGAGGTACCA
T3 Primer 3’
 pMT7T3 5’ primer  45 e CTAGTCTTTTTGTCTTTTAT T7  Pimer 5’
NotesFragment
length
Annealing
temp.
Sequence (5’ f  3’)Primer
Hypoxanthin-Guanin-Phosphori
bosyl-Transferase; Wiles, 1995
249 bp50-55 g CCACAGGACTAGAACACCT
GC
RT-HPRT 3’
Hypoxanthin-Guanin-Phosphori
bosyl-Transferase;  Wiles, 1995
249 bp50-55 h CGCTGGTGAAAAGGACCTC
T
RT-HPRT 5’
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xenopus N208 bp54 i CGGTAGGCCCTTGCGGTGT
GA
 RT-XSmad1 N 3’
xenopus N208 bp54 j CAGAGGCTGCTTGGTTGGRT-XSmad1 N 5’
xenopus C320 bp53.8 k CGGGGGCCGTGCAGGTGAA
T
 RT-XSmad1 C 3’
xenopus C320 bp53.8 l CCTATGTTGGGGGTTGAAG
TCTAT
 RT-XSmad1 C 5’
xenopus(N+P) 443 bp58.2 m CCGGAATTGCGCAAGGAGA
CTGT
 RT-XSmad1 NP 3’
xenopus(N+P)443 bp58.2 n CACCAGCCCAGCAGTGAAG
AGG
 RT-XSmad1 NP 5’
human, Canada589 bp55 o CTCTCCTCTGTTGATTTCTG
A
RT-CHMAD 3’
human, Canada589 bp55 p CACTGTGTCACCATTCCCCG
CTCTC
RT-CHMAD 5’
xenopus1310 bp576AGAGACCGAGGAGATGGG
ATTATG
RT-Smad1 3’ xen
xenopus1310 bp57,6GAAATGGGCAGAGAAAGC
AGTAGA
RT-Smad1 5’ xen
MUR469 bp59.6 q CCTACCGGCTGTTGAAGAT
GACCTC
RT-Smad7 3’
MUR469 bp59.6 r CTCGCGTGGGGAGGCTCTA
CTGTGT
RT-Smad7 5’
MUR745 bp64.5 s CGGTGCTCGCCCCGGTTGT
AGG
RT-Smad6 3’
MUR745 bp64.5 t CGCCCGCTCGCGACTGCTG
CTTCT
RT-Smad6 5’
DPC4 (MUR)502 bp60.2 u CCACGGGGTTTCCTTGATG
CTCT
RT-Smad4 3’
DPC4 (MUR)502 bp60.2 v CCTTCGGGAGGAGATCGCT
TTTG
RT-Smad4 5’
MUR836 bp58.7 w CCCAGCTCTACCCTCCGGC
GTGTTC
RT-Smad3 3’
MUR836 bp58.7 x CCAGTGCTATTTTCGTCCAG
TCTCC
RT-Smad3 5’
MUR472 bp55.2 y CAAGTGCTGTTTTTGCTCTG
GA
RT-Smad2 3’
MUR472 bp55.2 z CTGTTTGCTGAGTGCCTAAG
TGATA
RT-Smad2 5’
MUR531 bp59 { CGCTGTTGACGCTTTGGTG
AA
RT-Smad1 5’
MUR531 bp59 | CGCTGGTTGGGGAGTGAGG
GTAGGT
RT-Smad1 3’
NotesFragment
length
Annealing
temp.
Sequence (5’ }  3’)Primer
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MUR473 bp59 ~ CGGCTTCTTGGTCCATCTGT
CC
RT-PTH/PTHrP R 3’
MUR473 bp59  CGTTGCCATCATATACTGTT
TCTGC
RT-PTH/PTHrP R 5’
pCS2 3‘ primerAATACGACTCACTATAGRT-pCS2 3’
pCS2 5’ primerCCCAACTTGATTTAGGTGA
C
RT-pCS2 5’
MUR423 bp53  CTTTGCCTGCCTCTACATAC
ATTTT
RT-Osteopontin 3’
MUR423 bp53  CACATCAGAGCCACGAGTTT
CACA
RT-Osteopontin 5’
MUR488 bp59.7  CGGGGGTAATGGGAGGGGT
GAC
RT-Osteonectin 3’
MUR488 bp59.7  CCCCTCTGCGCATCGGTGA
CT
RT-Osteonectin 5’
MUR419 bp57  CGAGCTGCTGTGACATCCAT
AC
RT-Osteocalcin 3’
MUR419 bp57  CGCAGACCTAGCAGACACC
AT
RT-Osteocalcin 5’
xenopus(C+P) 5’56.1  CGCCTCACAACGCAACTTTT
C
RT-XSmad1(del
1-144)
xenopus P285 bp55  CGCCTGGACATCTGCTCTAT
T
RT-XSmad1 P 3’
xenopus P285 bp55  CGCCTCACAACGCAACTTTT
C
RT-XSmad1 P 5’
NotesFragment
length
Annealing
temp.
Sequence (5’   3’)Primer
Notes: All the primers were purchased from firm Gibco.
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7.2 Plasmids
Dirks, W. (Genetic, GBF,
Braunschweig) (Ahrens et al.
1993)
used as an eukaryotic expression
plasmid
pMT7T3
PromegaLuciferase expression plasmid
lacks eukaryotic promoter and
enhancer sequences. The JunB
promoter was cloned in this vector.
pGL2-Basic
Kirchhoff, S. (Genetic, GBF,
Braunschweig)
used as a selection plasmid in
permanant transfections
pBSpAC^p
Promega(Colbe’re-Garapin,
1981)
used as a selection plasmid in
permanant transfections
pAG 60
Souce of supplyFunctionPlasmids
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7.3 Materials and Instruments
7.3.1 Instruments
autoclave Westerma Sauter LAF
cell culture documentation: INTAS 
cell culture incubator: Heraeus B 5061 EK/02
cool centrifuge: Sorvall Superspeed RC5-C with roter GS3, GSA, 
SS34 and HB-4
electrophoresis apparatus: Biometra, PP2000
electrotransformation apparatus: Bio-Rad Gene Pulser
gel documentation: PHASE, GelCam
lumat (for Luciferase)LB 9501: Berthold
microlumat (for ß-Gal) LB 96 P: EG & G Berthold
microtitlerplate(MTP) white: EG & G Berthold
microscope: Leitz, Labovert FS
PCR apparatus: Perkin Elmer, Gene AMP PCR System 2400
pH meter: 50 Beckman
photo meter: Spectronic, Genesys 2; Pharmacia, GeneQuant
shaking appartus: Heidorf Reax 2000
sequence apparatus: Pharmacia LKB-ALF DNA Sequencer
ABI Prism 310 Genetic Analyzer
sterile bank: Heraeus Lamin Air
table centrifuge: Heraeus Christ Biofuge A
Eppendorf 5417 R
thermomixer: Eppendorf Thermomixer 5436
vacuum centrifuge: Savant Speedvac Concentrator
waterbath: Haake D8-L, GFL model 1004 (Kötter)
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7.3.2 Materials and cell culture media
sterile filter: Sartorius membrane filter; Pore size 0,22 Ł m
cell culture flasks:  Nunc
FCS: CTM, Chemie-Technik-München
DME: GIBCO BRL
The other materials and instruments were standard laboratory equipmemts and had no relative
effects on documentations of experiments.
7.3.3 Enzymes and chemicals
The restriction endonucleases, alkaline phosphatase (Shrimp), T4-Polynucleotide kinase,
Klenow-Fragment, M-MLV-Reverse Transcriptase and Taq-DNA-Polymerase were supplied
by firm Biolabs, Boehringer, GIBCO BRL, Pharmacia, Promega and USB.
Chemicals were purchased from Bayer, Biolabs, Bio-Rad, Boehringer, Fluka, GIBCO BRL,
Merck, Pharmacia, Renner, Riedel-de-Haen, Roth, Seromed, Serva and Sigma.
7.3.4 Computerprograms/Data Banks
Adobe Photoshop 3.0 / 4.0
CorelDraw 7.0
DNASTAR 1.0
Excel 5.0
Medline
MVPilot 1.0 Zellkulturdokumentation
Vector NTI
WinCam 1.0
WIN GLOW
Lotus SmartSuite 97- Word Pro
7 Appendix
156
7.4 Abbreviations
A adenosine
Amp ampicillin
APS ammonium peroxydisulfate
ATP adenosine triphosphate
BamHI a restriction endonuclease
bFGF basic fibroblast growth factor
BMP bone morphogenetic protein
BSA bull serum albumin
bp base pair
ß-Gal ß-galactosidase
cDNA complementary DNA
dATP desoxyadenosin triphosphate
dCTP desoxycytidin triphosphate
ddATP didesoxyadenosin triphosphate
ddCTP didesoxycytidin triphosphate
ddGTP didesoxyguanosin triphosphate
ddTTP didesoxythymidin triphosphate
DEPC diethylpyrocarbonate
dGTP desoxyguanosin triphosphate
DMSO dimethylsulfoxid
DNA desoxyribose nucleic acid
dNTP desoxynucleotid triphosphate
dsDNA double-stranded DNA
DTT dithiothreitol
dTTP desoxythymidin triphosphate
E. coli Escherichia coli
E. coli SURE E. coli ‘Stop Unwanted Rearrengement Events’
EDTA ethylendiamine tetraactetic acid
EGF epidermal growth factor
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Erk extracellular stimulus responsive kinase
EtBr ethidium bromid
EtOH ethanol
FCS fetal calf serum
g gram
hr hour
HEPEs N-2-Hydroxyethylpiperazin-N’-2-ethanesulfonic acid 
HindIII a restriction endonuclease
kb 1000 base pair
Kv kilovolt
l liter
LMP low melting point
M molar concentration
mA milliampère
Mad mothers against dpp
mg milligram
min minute
ml milliliter
mM millimol
mRNA messenger RNA
 micro
 g microgram
 l microliter
 m micrometer
NaAc sodium acetate
ng nanogramm
nm nanometer
nmol nanomol
OD optical density
PCR polymerase chain reaction
RNA ribonucleic acid
RNase ribonuclease
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RNasin RNase inhibitor
rpm rounds per minute
RT room temperature
RT-PCR reverse transcription polymerase chain reaction
SDS sodium dodecyl sulfate
sec second
ss sigle stranded
T thymidine
TE Tris-EDTA
TEMED N, N, N‘, N‘-tetramethyl ethylene diamine
TGF transforming growth factor
U unit
UV ultraviolett
Vol volume
w/v weight per volume
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